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ABSTRACT 
 
Despite major advances in therapies, chronic heart failure (CHF) and hypertrophic 
cardiomyopathy (HCM) are still associated with significant morbidity and mortality.  
These patients often have a significant limitation in their exercise capacity. We showed 
that there are widespread abnormalities of both systolic and diastolic function in HCM 
patients. These abnormalities contribute significantly to exercise limitation observed in 
these patients. Furthermore, we showed that HCM manifest a myocardial energy 
deficiency which was accompanied by a slowing of the energy-dependent early diastolic 
LV active relaxation during exercise. The present study supports the hypothesis that 
HCM is, at least in part, a disease of energy deficiency. Consistent with this hypothesis, 
we showed that metabolic modulation by perhexiline augmented myocardial energetics, 
and normalised diastolic ventricular filling which translated into significant subjective 
(improved symptoms) and objective (increased exercise capacity, peak VO2) clinical 
improvement in HCM patients. These findings suggest that metabolic modulators, such 
as perhexiline, have the potential role in the management of patients with symptomatic 
non obstructive HCM, a condition for which there are currently limited therapeutic 
options. However, large scale long-term studies are still required to examine the effects 
of these agents on morbidity and mortality in these patients. 
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CHAPTER 1: INTRODUCTION 
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Hypertrophic Cardiomyopathy 
Definition 
Hypertrophic cardiomyopathy (HCM) is defined as an autosomal dominant disease 
characterised by left ventricular hypertrophy in the absence of cardiac or systemic 
conditions (such as hypertension, aortic stenosis, or congenital heart defects) sufficient 
to explain the degree of hypertrophy (Figure 1). It is believed that myocyte and 
myofibrillar disarray provide the electrical substrate for malignant ventricular 
arrhythmias, which may be triggered by hypotension and/or ischaemia and/or a change 
in the autonomic milieu
1
.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Example of normal and HCM heart.  
Courtesy of Mayo Education 
HCM Normal 
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Classification of HCM 
There are different classifications of HCM depending on distribution of LV hypertrophy 
and on the presence or absence of significant LV Outflow Tract Obstruction (LVOTO) 
[gradient > 30 mmHg],   Figure 2.  Asymmetric septal hypertrophy (ASH) with and 
without LVOTO (Figure 2A and B respectively) is the commonest form of HCM. Other 
forms include concentric LVH (Figure 2C), apical HCM (Figure 2D) and mid cavity 
obstruction. 30% of HCM patients have obstruction at rest but this may increase with 
exercise and orthostatic stress. Some HCM patients may develop systolic heart failure at 
end stage due to left ventricular remodelling with progressive wall thinning and cavity 
enlargement.  A minority of HCM patients may have significant restrictive physiology. 
 
  
 
 
 
 
 
 
 
 
 
                                                    
   Figure 2: Anatomical classification of HCM.  
   Courtesy of Cardiomyopathy Association CMA 
A B 
D C 
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Genetics 
HCM is inherited in an autosomal dominant fashion with variable penetrance. There is 
considerable genetic heterogeneity at both locus and allelic level, and a wide range of 
phenotypic expression. It is a disease of the sarcomere, with >400 mutations having 
been identified in approximately 10 genes encoding cardiac contractile proteins.
2
 The 
main four genes that encode proteins of the cardiac sarcomere are:
 
the -myosin heavy-
chain, cardiac troponin T, myosin-binding protein C genes and
 
-tropomyosin, Figure 3.  
Figure 3: Component of Sarcomere in HCM.  
From Spirito et al, NEJM 1997 
3
 
 
 
Prevalence 
HCM is the commonest inherited cardiac condition. The estimated prevalence of 
phenotypically expressed HCM in the adult general population is about 0.2% (1: 500) 
4
.  
 33 
The actual prevalence is likely to be higher because patients with genotypic HCM who 
do not yet have hypertrophy are probably undetected clinically. 
 
Presentation 
Whilst some patients have minimal symptoms and/or a normal lifespan, others are 
highly symptomatic, and in others sudden cardiac death (SCD) may occur, which may 
or may not be preceded by symptoms of the disease.  HCM is the most common cause 
of SCD in young people (including trained athletes) in most series 
5-13
. Typical 
symptoms in HCM include breathlessness and/or fatigue on exertion, chest pains (which 
may be typically anginal, atypical, or a combination of both), palpitations (most 
commonly due to paroxysmal atrial fibrillation), and episodes of syncope or pre-
syncope (Figure 4). 
 
Outflow tract obstruction is present at rest in approximately one third of patients, but 
may be more frequent in situations associated with central hypovolaemia and or high 
sympathetic tone (dynamic obstruction). Outflow tract obstruction may contribute to 
symptoms and is usually amenable to pharmacological therapy (beta blockers and 
disopyramide), but in highly symptomatic medically refractory cases surgical septal 
myectomy or alcohol septal ablation may provide considerable symptomatic relief. 
 
In the majority of patients however symptoms are unrelated to outflow tract obstruction. 
Patients with HCM typically exhibit abnormalities of diastolic function and these are 
thought to be important in the genesis of breathlessness. Active relaxation is slowed and 
filling rate diminished at rest 
14
. 
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                                                            Presentation 
 
 
 
 
 
 
 
Figure 4: Broad spectrum of clinical presentations of HCM 
 
Furthermore our group showed that, on exercise there is frequently a failure of the 
normal increase in rate of active relaxation on exercise, indeed in some patient‘s active 
relaxation paradoxically slowed on exertion 
15
.  Whilst resting measures of diastolic 
function were rather poorly related to exercise capacity, time to peak filling [TTPF] (an 
indirect measure of active relaxation) during maximal exercise was strongly related to 
peak oxygen consumption 
15
. Izawa and colleagues subsequently confirmed these non 
invasive observations using invasive measures of active relaxation 
16
. They 
demonstrated a failure of the normal shortening of active relaxation as heart rate was 
increased by atrial pacing and during supine exercise. Verapamil improves resting 
 
Asymptomatic 
  
Angina 
 
Syncope & 
presyncope 
 
Palpitation 
 
Dyspnoea 
 
Sudden Death 
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diastolic filling parameters in the majority of patients with non obstructive HCM and 
improves symptoms in many, but not all 
14
. The mechanisms responsible for the 
diastolic dysfunction are probably multifactorial. The hypertrophy, myocyte disarray 
and fibrosis may increase passive left ventricular stiffness. Abnormalities of active 
relaxation may relate to abnormal calcium handling 
17
, to microvascular myocardial 
ischaemia, to mechanical dyssynchrony 
18
, or to impaired myocardial energy utilisation 
19
.  
 
Management 
 
There are four distinct issues in the management of HCM patients. These include 
treatment of symptoms
 
to improve quality of life (QOL), genetics testing, family 
screening and the identification of patients
 
who are at high risk for sudden death and 
require aggressive
 
therapy (Figure 5). 
 
Pharmacological options 
Conventional treatments include ß-blockers +/- disopyramide for obstructive HCM 
whereas calcium channel antagonists (mainly verapamil) are used for non-obstructive 
HCM. Beta Blockers act predominantly by lowering heart rate with a consequent
 
prolongation of diastole and increased passive ventricular filling 
20, 21
.
 
Beta-blockers 
exhibit negative inotropic effects which may lessen
 
myocardial oxygen demand and 
decrease the outflow gradient during
 
exercise 
20, 21
. Similarly, disopyramide may 
improve symptoms by reducing the outflow gradient via its inotropic effect 
22
. 
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Verapamil improves symptoms by increasing ventricular
 
filling as a result of heart rate 
reduction and probably reduces myocardial ischaemia 
23, 24
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The management of HCM.  
SCD: sudden cardiac death, H/O: history of, MWT: maximal wall thickness, ICD: Implantable 
Cardioverter Defibrillator, NSVT: Non-sustained ventricular tachycardia.  
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Dual Chamber (DDD) Pacemaker 
Nonrandomized, unblinded studies reported that dual-chamber pacing is associated with 
both a substantial decrease in the outflow gradient and symptomatic improvement in 
patients with outflow obstruction 
25, 26
. However, in a randomized, double-blind, 
crossover study, there was no significant difference in exercise capacity with and 
without pacing 
27
. Furthermore, there was only a small decrease in the average outflow 
gradient during pacing and varied significantly among patients 
27
. These findings 
suggest that the effects of DDD pacemaker to be less favourable. Additionally, there are 
concerns that pacing may have harmful effects on ventricular filling and cardiac output 
28, 29
. 
 
Alcohol septal ablation 
This is a percutaneous, intra-coronary, minimally-invasive procedure to relieve 
symptoms by reducing outflow gradient. 1 to 4 ml of alcohol is introduced into the 
target septal perforator coronary artery branch to produce myocardial infarction. This 
reduces basal septal thickness and enlarges the LV outflow tract.  
 
Surgical myectomy 
This is an invasive surgical operation which involves resection of a small amount of 
muscle (about 5 g) from the proximal septum thereby abolishing any significant 
obstruction to LV outflow. In established centres, it is considered as the gold standard 
treatment for adults with obstructive HCM and severe drug refractory symptoms.  
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Risk stratification for SCD 
HCM is considered the
 
most common cause of SCD in young competitive athletes 
10
. 
Ventricular fibrillation and tachycardia are the commonest cause of sudden death
 
in 
these patients. This can be a primary event related to the arrhythmogenic
 
myocardial 
substrate or as a secondary occurrence triggered
 
by myocardial ischaemia. All patients 
should undergo non-invasive risk factor stratification for SCD (Figure 5). Detailed 
history should be obtained specifically for any history of unexplained syncope, previous 
cardiac arrest and family history of sudden cardiac arrest. Echocardiogram is a useful 
tool to identify severe LV hypertrophy (MWT > 3 cm) and any significant LVOTO 
(gradient > 30 mmHg). NSVT on 48 hours tape is another important risk factor for SCD 
among these patients. Furthermore, an abnormal BP response during exercise is an 
important risk factor for SCD especially in young patients (less than 40 years old). This 
is defined as a failure to increase systolic blood pressure by > 25 mm Hg above the 
resting systolic blood pressure during exercise. Patients with two or more risk factors 
have annual sudden death rates of 3% (95% CI 2 % to 7%). These patients should 
be offered  prophylaxis with ICD and/or  (more controversially) amiodarone 
5
 (Figure 
5). 
 
Family screening 
All first-degree relatives of the HCM patient should be offered screening. This should 
include detailed history, physical examination, ECG and echocardiogram. Genetic 
testing is only helpful if a gene had been identified in the affected person. Screening is 
usually performed annually from age 12-20 and every 5 years age 25 and over.  
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Future Treatment 
While the incidence of sudden death appears to be declining, the management of 
symptoms remains a challenge. In particular, in non-obstructive HCM patients whose 
symptoms are refractory to standard drug therapy, there are no therapeutic options 
(unlike the options of surgical septal myectomy or alcohol septal ablation in obstructive 
disease), mandating a search for effective novel treatments. Small studies in animal 
models of HCM have shown regression of LV hypertrophy by simvastatin and losartan 
30, 31
. However, these results have not been replicated in human studies. There is a 
strong evidence of reduced cardiac energetic in both animal and human models of HCM 
32-36
. The main focus of this PhD thesis is to examine the causative role for this energy 
deficiency in the pathogenesis of HCM. Furthermore, the studies described assess the 
direct manipulation of myocardial energy utilisation with perhexiline, metabolic 
modulator, on subjective and objective clinical benefits in symptomatic non-obstructive 
HCM patients who were already on optimal medical therapy.  
 
 
Metabolic alteration in heart diseases 
The foetal heart uses glucose as its primary substrate, but a shift to predominant free 
fatty acid utilisation occurs soon after birth 
37
.  The healthy adult human heart is a 
metabolic omnivore 
38
, able to adapt substrate utilisation accordingly to circumstances 
but in general approximately 70% of energy production is derived from beta oxidation 
of fatty acids 
39, 40
 (Figure 6). During ischaemia there is a shift towards greater glucose 
utilisation, but free fatty acid utilisation is still typically more than 50% 
40
. Changes in 
cardiac substrate utilisation occur in the diseased heart. In animal models of left 
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ventricular hypertrophy (LVH) progressing to heart failure there is a down regulation of 
enzymes involved in fatty acid oxidation with an increase in glucose uptake 
41
. 
However, at least in the rat aortic banding model, there appears to be a block in the 
conversion of Pyruvate to Acetyl CoA. Although anaplerosis, process which replenishes 
the Tricarboxylic Acid (TCA)  cycle,  is increased this is insufficient to compensate for 
this block and the hypertrophied heart is energy deficient 
42
. The spontaneous 
hypertensive rat is deficient in CD36 (Cluster of Differentiation 36) which is an integral 
membrane protein required for the uptake of long chain fatty acids into cardiac 
myocytes 
43
.  Dietary supplementation with medium chain fatty acids (that do not 
require CD36 to enter myocytes) prevents the development of LVH and increases 
resistance to adrenergic stress in this model, suggesting that the reduction in fatty acid 
utilisation is maladaptive in this model 
44, 45
. In contrast, in the mouse banding model of 
LVH it appears adaptive because up regulating fatty acid utilisation by activating 
peroxisome proliferators-activated receptor alpha (PPAR-α) results in a loss of 
contractile function in this model 
46
. In rapid pacing models of heart failure fatty acid 
utilisation appears to be preserved or even increased 
47
.  
 
The mechanisms responsible for the shift to decreased fatty acid oxidation in LVH 
models the ‗foetal phenotype‘ are complex.  Increased Adenosine 5'-monophosphate 
[AMP] leads to activation of AMP-dependent protein kinase (AMPK) which acts as a 
‗low on fuel‘ warning system 48 .  Increased [AMP] and AMPK activity has been 
reported in hypertrophied rat hearts undergoing transition to heart failure 
49
.  By 
phosphorylating several proteins, AMPK regulates free fatty acid and glucose utilisation 
in both cardiac and skeletal muscle to maximise ATP production. This results in an 
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increase in (insulin independent) GLUT 1 transporters 
49
 and phosphorylation of 6- 
phosphofructo-2-kinase (pPFRK-2) which increases synthesis of fructose 2, 6 – 
bisphosphate (F2,6 bisphosphate), a potent stimulator of glycolysis 
50
.  AMPK also 
regulates fatty acid metabolism.  Acute increases in AMPK activity enhance fatty acid 
oxidation in rat skeletal muscle via a decrease in acetyl CoA carboxylase activity and a 
subsequent decrease in the inhibition of Carnitine palmitoyl-transferase-1 (CPT-1) by 
malonyl CoA 
51
 (Figure 6).  
 
 
Figure 6: Myocardial metabolism.  
With permission from Future cardiology 
52
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In contrast chronic AMPK activation by pressure overload was associated with 
decreased fatty acid utilisation via marked reductions in the expression of CPT-1 and 
medium chain acetyl CoA dehydrogenase (MCAD), the rate limiting steps for this 
pathway 
49
.   Increased AMPK activity also increases expression of the nuclear 
transcription factor peroxisome proliferators-activated receptor gamma co-activator 
(PPAR-γ). This promotes mitochondrial biogenesis and oxidative phosphorylation 53, 54. 
 
In contrast to LVH models, most studies of rapid pacing models have shown increased 
dependency on FA metabolism 
47
. However, one study in the rapid pacing canine heart 
failure model showed a marked reduction in fatty acid utilisation and an increase in 
glucose utilisation and that was attributed to reductions in the expression and activity of 
Retinoid X receptor alpha (RXR-alpha), a nuclear receptor known to stimulate 
expression of enzymes involved in free fatty acid oxidation, and of the enzyme MCAD. 
55
.  There was no change in expression of PPAR alpha. The mechanisms responsible for 
altered expression and activity were not delineated. In contrast to the rapid pacing 
model, in pressure overload hypertrophy there is also down regulation of PPAR alpha 
expression 
56
. 
 
There remains some controversy as to whether the shift towards glucose utilisation in 
animal models of Left Ventricular Hypertrophy (LVH) and heart failure is adaptive or 
maladaptive.  Human genetic disorders of fatty acid beta oxidation may be associated 
with the development of heart failure 
57
.  The spontaneously hypertensive rat has an 
impaired ability to withstand adrenergic stress 
58
.   This appears to be because the 
reduced ability to utilise long chain fatty acids is not fully compensated under 
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conditions of stress by increased glucose utilisation, increased breakdown of 
intracellular triglycerides and increased flux through the anaplerotic reaction.  In this 
model dietary supplementation with medium chain fatty acids, which do not enter the 
myocyte via the defective Long Chain Fatty Acid (LCFA) transporter (CD36), prevents 
the development of left ventricular hypertrophy 
59
 and restores the ability to withstand 
acute adrenergic stress 
58
 .  These observations suggest that the shift to glucose 
utilisation may be maladaptive.  On the other hand, cardiac specific over expression of 
the GLUT 1 transporter prevents the transition from left ventricular hypertrophy to heart 
failure in mice subjected to pressure overload 
60
 , whereas activation of the PPAR alpha 
receptor (which increases fatty acid utilisation) in the mouse aortic banding model, 
causes contractile dysfunction 
46
.  
 
It appears that the direction of the metabolic substrate shifts varies with aetiology and 
severity of ventricular dysfunction 
61
.  Therefore, the severity of heart failure and 
temporal differences during the progressive remodelling that characterised the transition 
to heart failure may play important role in the mechanism of metabolic substrate shift.  
Unlike the above animal experimental models that undergo transition from LVH to 
heart failure and in which there is a shift to a ‗foetal‘ pattern of substrate use, the 
available evidence suggests that human heart failure may not be associated with a shift 
towards predominant glucose utilization, indeed the converse may be true 
62, 63
.  Using 
Positron emission tomography (PET) technique, Taylor et al demonstrated increased 
myocardial FFA uptake and reduced glucose uptake in human heart failure. There are 
several potential explanations for this.  Firstly, insulin resistance is commonly present in 
CHF 
64
.  Nikolaidis et al demonstrated a progressive increase in cardiac insulin 
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resistance during disease progression in the canine rapid pacing heart failure model 
65
. 
There was reduced cardiac basal and insulin stimulated glucose uptake (associated with 
reduced insulin-stimulated GLUT-4 translocation) 
65
. Secondly, increased plasma FFAs 
are characteristically found in CHF due to sympathetic activation and contribute to 
insulin resistance.  
 
Despite the uncertainty of whether the shift towards glucose metabolism in 
experimental models of heart failure is adaptive or maladaptive in nature, observations 
with perhexiline (8 weeks) 
66
 and those with trimetazidine (up to 18 months) 
67
 suggest 
that pharmacologically induced inhibition of fatty acid metabolism has beneficial effects 
on  cardiac performance, exercise capacity and symptoms in patients with chronic heart 
failure. 
 
Substrate Utilisation and Myocardial Oxygen Utilisation 
 
Simple stochiometry suggests that utilisation of fatty acids should cost approximately 
12% more oxygen per unit of ATP generated than glucose. In practice the increased 
oxygen requirement when plasma FFAs are increased compared with dominant glucose 
utilisation appears to be substantially greater (up to 40 %) 
68-70
, implying the presence of 
an ‗oxygen wasting‘ phenomenon with FFA usage. In the isolated perfused rat heart, 
increasing the palmitate and octanoate in the perfusate disproportionately increased 
oxygen utilisation and this was only partially abolished by administration of an inhibitor 
of fatty acid beta oxidation, suggesting that a component of the oxygen ‗wasting effect‘ 
of increased FFAs is not related to mitochondrial long chain fatty acid oxidation 
71
.  It is 
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possible that it may be due to the up-regulation of uncoupling protein expression in the 
mitochondria via FFA activation of peroxisome proliferators-activated receptor alpha 
(PPAR ) 72. Normally the electron transport chain results in the generation of a net 
proton gradient across the inner mitochondrial membrane (IMM) and very little proton 
leak occurs and all the energy built up in the respiratory chain can be used to 
phosphorylate ADP to generate ATP. When mitochondria are ‗uncoupled‘ there is 
proton leakage and the electrochemical gradient is dissipated as heat 
73
. Emerging 
evidence suggests that the primary role of uncoupling proteins (UCP) is the export of 
lipid peroxides and long chain fatty acids out from the mitochondrion. This protects 
mitochondrial DNA from oxidation damage. Uncoupling occurs when fatty acid 
delivery exceeds oxidative capacity and when there is an accumulation lipid peroxides 
73
. The activity of UCPs is also increased by lipid peroxides. Heart failure is associated 
with elevated free fatty acid concentrations which might increase uncoupling.  
Consistent with this concept, Murray et al showed that mitochondrial uncoupling 
protein expression in human cardiac muscle correlated positively with plasma FFA 
concentration 
74
. Furthermore, high levels of FFA may trigger intracellular futile 
metabolic cycles such as intramyocardial lipolysis and resterification 
69, 75, 76
.  
 
Myocardial energetics in Heart Diseases 
Heart Failure 
 
Heart failure continues to have a significant morbidity and mortality despite the several 
advances in treatment such as additional neurohumoral blockades and cardiac 
resynchronisation therapy.  There is compelling evidence that an impairment of cardiac 
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energetic status may play an important role in the pathophysiology of heart failure even 
in the absence of coronary artery disease. Studies of human biopsy specimens and 
others using in vivo 
31
P NMR spectroscopy suggest that [ATP] is approximately 25-
30% lower in the failing human heart. Studies in animal models have shown that there is 
a global loss of the total adenine nucleotide (TAN) pool 
77, 78
. It is not clear whether this 
is a consequence of reduced (or inadequate) De Novo purine synthesis or increased 
breakdown to diffusible purine nucleosides. The energetic abnormality may in turn 
exacerbate the loss of TAN in that increased [AMP] activates cytosolic 5‘AMP –
specific 5‘nucleotidase, the primary enzyme responsible for the conversion of AMP to 
adenosine in muscle cells. Shen and colleagues investigated the changes in energetic 
status occurring during the evolution of heart failure in the canine rapid pacing model.   
There was a progressive monotonic decay in total adenine nucleotides and creatine from 
the onset of pacing.  In other words, the onset of the decline in energetic status preceded 
objective evidence of cardiac contractile dysfunction 
77
.  
 
Phosphocreatine (PCr) is an important energy buffer molecule that maintains a high 
phosphorylation potential under conditions of increased energy demand such as 
exercise. The movement of a phosphoryl group from PCr to ADP by the enzyme 
Creatine kinase (CK) generates ATP approximately 10 times faster than the maximum 
rate of ATP generation via oxidative phosphorylation 
79
. Cardiac creatine content is 
determined in large part by the activity of the creatine transporter which is responsible 
for creatine uptake into the myocyte against a concentration gradient 
80, 81
.  Studies in 
animal models of LVH / heart failure and in human heart failure have shown that there 
is a progressive reduction in the creatine pool as high as 60% and the level of reduction 
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is related to heart failure severity 
82-84
.  In the healthy heart approximately two thirds of 
the total creatine pool is phosphorylated via the CK reaction to form PCr.   The 
reduction of total creatine pool in condition such as heart failure results in PCr depletion 
and also a reduction in PCr/ATP ratios as measured by 
31
P NMR spectroscopy 
48, 85
.  
The magnitude of the reduction of this ratio predicts mortality 
86
.  The reduction in PCr 
in heart failure appears to be partly due to a decreased number of creatine transporters 
81
 
and a reduction in CK isoenzyme expression activity, particularly mitochondrial CK 
leading to a reduced [PCr]/ [Total Creatine] 
87
.  The reduced mitochondrial CK activity 
may in turn be partly mediated by the effect of inducible nitric oxide synthase (iNOS)-
derived Nitric Oxide 
88
. Creatine supplements are frequently taken by competitive 
athletes, despite the fact that the myocyte levels are primarily limited by the transporter.  
Short term oral creatine supplementation in chronic heart failure (CHF) has been shown 
to increase skeletal muscle function, but no effect was observed on left ventricular 
ejection fraction (LVEF) 
89, 90
 .  In summary, there is clear evidence that even in the 
absence of coronary artery disease (or of myocardial hypoxia) there is reduced energy 
reserve in the myocardium in heart failure, which although related to heart failure 
severity, may begin before the development of overt heart failure. 
 
 
HCM 
Biochemical and biophysical analyses of the mutant sarcomeric proteins that cause 
HCM led Watkins and colleagues to propose that energy depletion may underlie HCM 
91-93
. Consistent with this, unexplained left ventricular hypertrophy is a feature of 
disorders associated with a variety of metabolic genes that lead to defects in energy 
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production in the heart 
91
. In a recent study using in vivo cardiac MR spectroscopy, 
resting PCr/ATP ratio was diminished in patients with sarcomeric HCM, indicating 
reduced energy availability 
34
.  Importantly, patients with genotypic HCM who do not 
yet have hypertrophy have a similar degree of impairment of cardiac PCr/ATP ratio as 
do patients with marked hypertrophy, implying that the disturbance may be an early 
feature of the disease and is not simply due to the hypertrophy 
32
. Consistent with this 
concept is the recent observation that although LVEF is normal or supra-normal in the 
majority of HCM patients, there is nevertheless usually impairment in long axis systolic 
function which is apparent even in young patients before hypertrophy develops 
94
.  
Tagged MRI studies have shown that radial contractile function may also be impaired 
even though EF is supra-normal 
95
.  
 
Anginal chest pains in HCM patients may be due to increased myocardial oxygen 
demand, a reduced transcoronary perfusion gradient, microvascular disease and 
potentially to the disturbed energy utilisation described above. Reduced skeletal muscle 
maximal oxidative capacity has also been reported in HCM patients with Beta Myosin 
mutations (expressed in skeletal muscle) but not in those with Troponin mutations 
96
.  
Whether this relates to a similar primary energetic disorder, to an impairment of skeletal 
muscle nutritive flow, or to skeletal myopathy is unknown 
97
. 
 
In summary there is clear evidence of an energetic impairment in both cardiac and 
skeletal muscle in HCM, whether due to ischaemia or abnormal energy utilisation.  
Exercise limitation in HCM patients appears to be due to a dynamic impairment of 
active relaxation during exercise, probably related to this energetic impairment.  From 
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the above it will be clear that an agent which increased the efficiency of myocardial 
energy production (i.e. increased production without increased oxygen cost) would have 
the potential to improve symptoms of breathlessness and angina in patients with HCM.  
 
Metabolic Agents 
In a study in the late 1990‘s intracoronary pyruvate was shown to acutely increase 
stroke volume and reduce pulmonary capillary wedge pressure in heart failure patients, 
implying acute beneficial effects of a shift away from fatty acid metabolism 
98
. This 
renewed interest in the potential beneficial effects of modifying substrate utilisation in 
chronic heart failure.  A number of pharmacological agents have been shown to inhibit 
FFA utilisation in the heart, either by inhibiting FFA uptake into the mitochondrion or 
by inhibiting beta oxidation (Table 1 and Figure 7).  
 
 
FFA uptake inhibitors 
 
Perhexiline 
 
Oxfenicine 
 
Etmoxir 
 
Beta-Blockers 
 
 
FFA β-Oxidation inhibitors 
 
Trimetazidine 
 
 
Others 
 
Ranolazine* 
 
D-Ribose 
 
Proprionyl-L-Carnitine 
 
Glucagon-like Peptide-1 
 
Table 1: Classification of metabolic agents.   
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Figure 7: Effects of metabolic agents on myocardial metabolism. 
With permission from Future cardiology 
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Some of these agents have been used as antianginal agents because of their ‗oxygen 
sparing‘ actions. Summary of clinical trials of metabolic agents are shown in Table 2. 
 
FFA Uptake Inhibitors 
Perhexiline 
Perhexiline is a metabolic modulator which causes a shift in cardiac substrate use from 
fatty acids towards carbohydrates.  It is a reversible inhibitor of both CPT1 and CPT2 
which are key enzymes involved in the transport of free fatty acids into the  
 51 
mitochondria
99, 100
. It is also effective as an adjunct to other anti-anginal therapies such  
as beta-blockades and calcium channel blockades. Its use however declined 
dramatically in the late 1970s and early 1980s following reports of hepatotoxic effects 
and peripheral neuropathy 
101-103
. 
 
Table 2: Summary of human clinical trials of metabolic agents for treatments of 
chronic heart failure.  
 
 
Metabolic 
Agents 
 
Study (Ref) 
 
Study 
design 
 
No of 
Patients 
 
Patient Characteristics 
 
Study 
duration 
 
Outcome 
Perhexiline 
Lee et al 
2005 66 
R PCT* 
Double 
blind 
56 
 EF≤ 45 
Non-ischemic & Ischemic CHF 
NYHA II-IV 
2 months 
Improvement in: 
LVEF 
 Peak Vo2 
 QOL 
Trimetazidine 
Vitale C et al 
2004 104 
R PCT 47 
EF< 50% 
Chronic stable angina 
NYHA I-III 
6 months 
 Improvement in:   
LVEF 
QOL 
 
Trimetazidine 
Di Napoli et 
al 2005 67 
Open label 61 
LVEF <40% 
Ischemic LV dysfunction 
NYHA II-IV 
18 
months 
 Improvement in: 
LVEF 
NYHA 
 
Trimetazidine 
Fragasso G et 
al 2006 105 
Open label 55 
LVEF<45% 
Ischemic and Non-ischemic 
CHF 
NYHA II-III 
13 
months 
 Improvement in:   
LVEF 
NYHA 
 
Etomoxir 
Schmidt-
Schweda et al 
2000 106 
Open label 10 
LVEF<40% 
Dilated Cardiomyopathy 
NYHAII-III 
3 months 
 Improvement in  
LVEF 
Increased stroke 
volume during 
exercise 
Etomoxir 
Holubarsch 
CJ et al 2007 
107 
R PCT 350 
LVEF<40% 
Ischemic and Non-ischemic 
moderate CHF 
NYHA II-III 
6 months 
Study stopped 
prematurely 
because of 
hepatotoxicity. 
D-Ribose 
Omran  
et al 2003 108 
R PCT 
Cross over 
15 
Ischemic Cardiomyopathy 
NYHA II-III 
3 weeks 
Improved 
functional 
capacity and 
diastolic function 
L-Carnitine 
Anand  
et al 1998 109 
R PCT 
Single 
blind 
30 
LVEF<40% 
NYHA II-III 
Ischemic and non-ischemic 
cardiomyopathy 
4 weeks 
 Improvement in:     
Peak VO2 but  
no change in 
LVEF 
 
L-Carnitine 
Eur Heart 
Journal 1999 
110 
R PCT 
Double 
Blind 
537 
LVEF <40% 
NYHA II-III 
Ischemic and non-ischemic 
cardiomyopathy 
6 months 
No increase in 
exercise capacity 
 
Glucagon-like 
Peptide 1 
Sokos  
et al 2006 111 
 Open label  12 NYHA III-IV 5 weeks 
 Improvement in:     
LVEF 
QOL 
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These effects were later demonstrated to occur in patients, in whom hydroxylation was 
slow because they processed a genetic variant of the cytochrome P450 2D6 enzyme, 
which metabolizes the drug, resulting in drug accumulation and, consequently, 
accumulation of phospholipids in the liver and nerves 
112
. The risk of toxic effects is 
virtually eliminated by maintaining plasma concentrations at between 150 and 600 
ng/ml, at this level the drug also remains efficacious 
113, 114
.  As a result, in some 
countries particularly Australia, the perhexiline use has been rekindled as an adjunctive 
therapy for refractory angina, with good results.   
 
In the therapeutic range, perhexiline has no effects on systemic vascular resistance and 
is not negatively inotropic 
115-117
. Horowitz and colleagues showed that perhexiline 
improve mechanical efficiency but without alteration in FFA uptake 
118
.  In a double-
blind, randomized, placebo-controlled trial, our group have shown short-term beneficial 
effects of perhexiline in patients with ischaemic or non-ischaemic heart failure 
66
. 
Patients taking optimum conventional medical therapy were randomized to perhexiline 
or placebo for 8 weeks, with dummy dose adjustment in the placebo group. We noted a 
large increase in the combined primary endpoint of peak oxygen uptake (≈ 3 ml/kg/min) 
and LVEF (≈ 10 percentage points), and improvement in symptoms as assessed by the 
Minnesota Living with Heart Failure (MLHF) Questionnaire. The study design involved 
separate randomization of the ischaemic and non ischaemic groups, permitting separate 
analysis of the primary endpoint in each group. Maximum oxygen uptake was 
significantly increased in both the ischaemic and non-ischaemic groups; therefore 
suggesting the mechanism of benefit is not primarily anti-ischaemic. The study was 
however of short duration and therefore, further work is required to show that the 
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clinical benefits of perhexiline are prolonged and that it reduces hospitalization and 
mortality.  
 
Oxfenicine 
Oxfenicine is an irreversible inhibitor of carnitine palmitoyltransferase I (CPT1). 
Oxfenicine has been shown to delay development of terminal heart failure, attenuate 
adverse hemodynamic changes, prevent wall thinning, prevent the activation of matrix 
metalloproteinases, and result in the transcriptional down regulation of CPT1 and of key 
enzymes involved in cardiac energy metabolism in animal models of heart failure 
119
. 
However a dose related increase in cardiac weight due to uniform myocardial fiber 
hypertrophy of all cardiac chambers was noted in animal studies 
120
. There was an 
increase in liver and kidney weights as well 
121
. No human studies have been reported 
with use of oxfenicine in heart failure. 
 
Etomoxir 
Etomoxir an irreversible inhibitor of CPT1 was initially introduced as a therapy for 
diabetes due to its hypoglycemic properties 
122, 123
. It has been shown to favorably 
modify ventricular mass, geometry and function in pressure-overloaded rats 
124
, and 
reduce the occurrence of ventricular failure in diabetic rat hearts 
125
. In humans, a 3-
month period, open-label, uncontrolled trial in 10 patients with NYHA class II–III heart 
failure, etomoxir treatment in addition to standard therapy significantly improved 
LVEF, cardiac output at peak exercise, and clinical status 
106
. However, recently a large 
randomized placebo controlled study was terminated prematurely because of the 
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development of significant hepatotoxicity in four subjects 
107
. Therefore etomoxir may 
not be a suitable metabolic modulator for use in heart failure. 
 
Beta Blockers 
β-adrenoreceptor blockade improves left ventricular function and prognosis in patients 
with ischaemic or nonischaemic cardiomyopathy 
126, 127
.  Interestingly, Wallhaus et al. 
demonstrated carvedilol in patients with heart failure caused a 57% reduction in 
myocardial free fatty acid uptake 
128
. However, neither mean myocardial uptake of 
labeled glucose tracers nor the rates of glucose use were significantly increased. This 
could be because of a type II error, since a marked fall in the ratio of myocardial free 
fatty acid to glucose use does suggest a so-called metabolic shift. This effect may be due 
to CPT1 inhibition. In another study, Al-Hesayen and colleagues showed that after 4 
months of carvedilol therapy, myocardial lactate consumption was increased and 
myocardial uptake of free fatty acids in patients with CHF was reduced 
129
.  This 
suggests that carvedilol therapy may cause a significant shift in myocardial substrate use 
from free fatty acids to glucose.  
 
FFA β-Oxidation inhibitors 
Trimetazidine 
There remain controversies regarding the exact mechanism of action of trimetazidine.  
Kantor and colleagues showed that trimetazidine reduces the oxidation of free fatty 
acids via inhibition of the enzyme long-chain 3-ketoacyl coenzyme A thiolase (LC 3-
KAT), which is crucial in the β-oxidation pathway 130. However, recent data failed to 
replicate these finding. In fact, MacInnes and colleagues showed that trimetazidine 
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exhibits anti-anginal effects without any significant inhibition of LC 3-KAT or any 
component of ß-oxidation 
131
. It is an effective anti-anginal agent with no significant 
vasodilator properties at rest or during dynamic exercise 
132
. In a double-blind, placebo-
controlled trial involving 47 patients with coronary artery disease and a reduced left 
ventricular function, limited by angina but not by heart failure, trimetazidine therapy 
improved left ventricular systolic and diastolic function and QOL 
104
.  
 
A number of other studies also demonstrated benefits with trimetazidine. Di Napoli et al 
demonstrated in an 18 month, open-label study a significant improvement in left 
ventricular function in patients with ischaemic cardiomyopathy with reduced LVEF 
67
. 
Patients were excluded if they had experienced acute myocardial infarction less than 3 
months previously, or had acute heart failure.  Many patients however were taking 
suboptimum conventional therapy. Rosano and colleagues demonstrated improvements 
in LVEF among patients with diabetes and coronary heart disease and left ventricular 
systolic dysfunction, but without frank heart failure, following 6 months of 
trimetazidine therapy 
133
.  
 
Recently, Fragasso et al demonstrated in patients with both ischaemic and non-
ischaemic cardiomyopathy increase in LVEF and NYHA class with the use of 
trimetazidine 
105
. However, in another study, which assessed the effects of trimetazidine 
in patients with heart failure who were diabetic, revealed no significant improvement in 
exercise capacity and only minor effects on left ventricular systolic function in both 
resting and exercise states 
134
.  
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Others 
Ranolazine 
Ranolazine has been shown to be a partial inhibitor of fatty acid β oxidation in vitro 135, 
136
, but this has not been reliably replicated in vivo. There is emerging evidence that 
ranolazine blocks the late cardiac sodium current 
137
. Ranolazine reduces sodium entry 
into ischaemic myocardial cells and, therefore, is thought to indirectly reduce calcium 
uptake via the sodium–calcium exchanger, to preserve ionic homeostasis, and to reverse 
ischaemia-induced contractile dysfunction 
138
.  
 
The drug has been shown to be an effective anti-anginal drug 
139, 140
. In a study of a 
canine microembolization model of heart failure, intravenous ranolazine increased 
myocardial work without increasing myocardial oxygen use, which implies an increase 
in cardiac efficiency 
141
. Acute intravenous administration of ranolazine has also 
improved left ventricular systolic function in dogs with heart failure 
142
. So far there 
have been no studies looking at the effects of ranolazine in humans with chronic heart 
failure.  
 
There are reports that the drug slightly prolongs the QT interval on electrocardiograms. 
This effect raises concerns about possible complications such as torsade de pointes 
polymorphic ventricular tachycardia and SCD 
143
. Therefore, the long-term safety of 
ranolazine needs further investigations. 
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Glucagon-Like Peptide 1 
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both 
insulinotropic and insulinomimetic properties with resultant increases in myocardial 
glucose uptake.  In a dog model of heart failure, GLP-1 improved LV function and 
systemic hemodynamic 
65
. In a small open label study, chronic infusion of GLP-1 
significantly improved left ventricular function, functional status, and QOL in patients 
with severe heart failure 
111
. GLP-1 is administrated subcutaneously because of 
breakdown in the gut. GLP-1 is currently unsuitable for oral or IV injection due to the 
rapid enzymatic degradation of the molecule by dipeptidyl peptidase IV (DPP-IV) 
enzyme 
144
.  Inhibitors of this enzyme are recently launched for treatment of diabetes 
145
. Coadminstration might allow oral administration of GLP-1.  
 
D-Ribose 
D-Ribose is a pentose sugar which enhances ATP production by entering the pentose 
phosphate pathway and bypassing rate limiting steps of glycolysis. Omran et al studied 
the effect of ribose supplementation on cardiac hemodynamics and QOL in patients 
with ischaemic cardiomyopathy. This was a prospective, double blind, randomised, 
cross over design study which showed improved QOL and improved diastolic function 
with ribose supplementation 
108
. However this has not been confirmed with large scale 
studies. 
 
Proprionyl-L-Carnitine 
Previous studies have demonstrated carnitine deficiency in heart failure patients 
146-148
. 
Carnitine is an important co-factor in intermediary metabolism of the myocardium 
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which improves utilisation of pyruvate in the Krebs cycle. Studies with carnitine 
supplementation have shown mixed results. A small study by Anand et al showed 
improvement in peak VO2 but no change in EF 
109
. However a larger study in 1999 with 
537 patients showed no improvement in exercise capacity 
110
. 
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CHAPTER 2: STUDY OBJECTIVES 
 60 
Study Objectives 
First aim: 
To measure peripheral metabolic rate in CHF patients at rest and to compare it with 
that in age-matched healthy volunteers (HVs).  
 
Hypothesis: we hypothesize that resting skeletal muscle oxygen consumption is 
reduced in CHF patients as compared to age-matched HVs. 
 
Second aim: 
To assess the roles of left ventricular strain and untwist in limiting exercise capacity 
in HCM patients.  
 
Hypothesis: we hypothesize that despite hyperdynamic LV systolic function, 
patients with HCM exhibit abnormalities of left ventricular strain and untwist as 
compared to age and gender matched controls. These abnormalities may contribute 
significantly to exercise limitation observed in these patients. 
 
Third aim:  
To evaluate the reproducibility and feasibility of performing cardiac 
31
P magnetic 
resonance spectroscopy (MRS) to measure high energy phosphate myocardial 
kinetics using 3 Tesla Philips MR scanner. 
 
Hypothesis: higher field strength of 3T offers better spatial resolution and signal to 
noise ratio (SNR) than conventional 1.5T. We hypothesize that 
31
P magnetic 
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resonance spectroscopy of the myocardium at 3T is feasible and reproducible in the 
measurement of high energy phosphate kinetics. This non-invasive in-vivo technique 
will allow the assessment of metabolic modulation effects of perhexiline on cardiac 
energetic in HCM patients. 
 
Fourth aim: 
To assess the relationship between cardiac energetics and diastolic function at rest 
and during exercise in HCM patients.  
 
Hypothesis: we hypothesized that impaired cardiac energetics may lead to diastolic 
dysfunction in symptomatic HCM patients.    
 
 
Fifth aim:  
To assess the effect of a metabolic agent, perhexiline, on cardiac energetics in HCM 
patients.  
 
 Hypothesis: we hypothesized that the metabolic modulator, perhexiline would 
ameliorate myocardial energy deficiency in symptomatic HCM patients.  
 
 
Sixth aim: 
To assess the effects of a metabolic agent, perhexiline, on symptoms and exercise 
capacity in HCM patients.  
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Hypothesis: we hypothesized that the metabolic modulator, perhexiline would 
ameliorate myocardial energy deficiency and thereby improve symptoms and 
exercise capacity in symptomatic HCM patients.   
 
  
Seventh aim: 
To assess the effects of a metabolic agent, perhexiline, on resting and dynamic 
diastolic dysfunction in HCM patients.  
 
Hypothesis: we hypothesized that the metabolic modulator, perhexiline would 
ameliorate myocardial energy deficiency and thereby improve resting and dynamic 
dysfunction in symptomatic HCM patients.   
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CHAPTER 3: METHODS 
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Transthoracic Echocardiography 
 
Echocardiography was performed with participants in the left lateral decubitus position 
with a GE Vivid 7 echocardiographic machine [Horten, Norway] and a 2.5-MHz 
transducer.  Measurements were averaged for 3 beats and were stored digitally and 
analyzed off-line.  Resting scans were acquired in standard long and short parasternal 
basal level (at mitral valve), papillary muscle level, and apical level (distal LV cavity 
where papillary muscle is not visible) as previously described 
149
 as well as apical 4-
chamber and apical 2-chamber axis.   
 
LV volumes were obtained by biplane echocardiography, and LVEF was derived from a 
modified Simpson‘s formula 150.  LA volumes were measured by area length method 
from apical 2 and 4 chambers as previously described 
150
 and indexed to body surface 
area to derive LA volume index (LAVI).  LV mass was measured by area length method 
and indexed to body surface area to derive LV mass index as previously described 
151
. 
The greatest thickness measured in the LV wall at any short axis parasternal view was 
considered to represent maximal wall thickness (MWT) in HCM patients 
13
.  
 
A pulse wave Doppler sample volume was placed at the mitral valve tips to record 3 
cardiac cycles.  Mitral annulus velocities (pulse wave tissue Doppler imaging [PW-
TDI]) were recorded from basal anterolateral and basal inferoseptal segment in apical 4-
chamber view. Subjects with poor echocardiographic windows were excluded from 
analysis. 
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Speckle Tracking Echocardiography (STE) 
 
STE is a non-invasive tool which allows measurement of strain, strain rate and rotation 
from grey echocardiographic images. It simply tracks characteristic speckle patterns 
created by interference of ultrasound beams in the myocardium which is based on 
greyscale B-mode images, independently of both cardiac translation and the insonation 
angle 
152
.  STE was measured using Echopac workstation (version 4.2.0.) [GE Medical 
System, Horten, Norway].   
 
In this speckle tacking method 
153-155
, the displacement of speckles of myocardium in 
each spot were analyzed and tracked from frame to frame.  We selected the best-quality 
digital two-dimensional image cardiac cycle and the left ventricle (LV) endocardium 
was traced at end-systole 
156
.  The region of interest width was adjusted as required to fit 
the wall thickness.  The software package then automatically tracked the motion 
through the rest of the cardiac cycle.  Adequate tracking was verified in real time.  A 
tracking score of ≤ 2.5 was accepted with frame rate between 60-100 Hz.  LV peak 
Strain and Strain Rate in each view were calculated with the use of the entire length of 
the LV myocardium.  The basal and apical LV global rotation (rot) and LV rotation rate 
(rot-r) STE data were measured from basal and apical short axis view respectively and 
were then exported to a spreadsheet program (Excel 2003, Microsoft Corp, Seattle, 
Washington) and then exported to DPlot Graph Software (2001-2008 by HydeSoft 
Computing, Inc, Vicksburg, Mississippi, USA) to calculate LV twisting and untwisting 
rate 
157
 (Figure 8).   
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At apical level, the LV rotates counter clockwise as viewed from apex and results in a 
positive value during systole, whereas the base rotates clockwise and results in a 
negative value, as in this representative case. To adjust for heart rate, R-R interval was 
converted to 100 %. Left ventricular twist was calculated as the simultaneous net 
difference between apical and basal rotation.  Left ventricular twist rate was calculated 
as a differential curve of the twist curve.    
Twist Rate Peak S
Peak Twist 
25% Untwist Peak Apical 
Rotation  
Peak Basal
Rotation  
Twist Rate Peak E
Twist Rate Peak A
 
Figure 8: Illustration of STE measurement of rotation and twist.    
Green line represents global apical rotation whereas red line represents global basal rotation.  
Black dotted line represents left ventricular twist which was calculated as the simultaneous net 
difference between apical and basal rotation.  Blue dotted line represents the left ventricular twist 
rate which was calculated as a differential curve of the twist curve.  
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Cardiopulmonary exercise test 
 
This was performed using a Schiller CS-200 Ergo-Spiro exercise machine, [Baar, 
Switzerland] (Figure 9) which was calibrated before every study. Subjects underwent 
spirometry and this was followed by symptom-limited erect treadmill exercise testing 
using a standard ramp protocol with simultaneous respiratory gas analysis 
158, 159
. 
Samplings of expired gases were performed continuously, and data were expressed as 
30-second means.  Minute ventilation, oxygen consumption, carbon dioxide production, 
and respiratory exchange ratio (RER) were obtained.  Peak oxygen consumption (peak 
VO2) was defined as the highest VO2 achieved during exercise and was expressed in 
ml/min/kg.  
 
Figure 9: Schiller CS-200 Ergo-Spiro exercise machine 
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Blood pressure and ECG were monitored throughout.  Participants were encouraged to 
exercise to exhaustion with a minimal requirement of RER > 1.  
 
Cardiac 
31
P MRS 
Magnetic resonance spectroscopy (MRS) is a non-invasive technique which allows in-
vivo assessment of cardiac energetics. 
31
P MRS measures the high energy phosphates 
PCr, three phosphate components of adenosine triphosphate (ATP), 2,3 
Diphosphoglycerate (2, 3-DPG) and phosphodiester compounds (PDE), (Figure 10). 
 
 
Figure 10: An example of a typical 
31
 P cardiac spectra. 
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PCr is an important energy buffer molecule that maintains a high phosphorylation 
potential under conditions of increased energy demand such as exercise (Figure 11). 
The movement of a phosphoryl group from PCr to ADP by the enzyme Creatine kinase 
(CK) generates ATP approximately 10 times faster than the maximum rate of ATP 
generation via oxidative phosphorylation 
79
. PCr/ATP ratio reflects the energetic state of 
the myocardium. The magnitude of the reduction of this ratio predicts mortality in heart 
disease 
86
. 
 
ATP ADP + P + Energy
ATPase
PCr
Creatine
Phosphokinase
Cr + P + Energy
Oxidative 
Metabolism
 
Figure 11: Creatine Phosphokinase reaction.  
 
31
P cardiac magnetic resonance spectroscopy was performed using a Phillips Achieva 
3T scanner (Figure 13) and a linearly polarized transmitter and receiver 
31
P coil with a 
diameter of 14 cm (Figure 14).  Localization was achieved by ISIS (image-selected in 
vivo spectroscopy) 
160
 volume selection. The participants were positioned supine with 
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the coil directly over the precordium. The coil was secured in place by straps wrapped 
around the upper body and coil. The participants were then positioned inside the magnet 
with the centre of the coil at the isocentre of the magnet. Survey images were obtained 
to check the position of the coil (Figure 12). The subjects and/or the coil were 
repositioned if required to ensure that the distance between coil and septum and apex of 
the heart was minimized. 
Voxel of acquisition Centre of the 31P coil
 
Figure 12: Position of voxel of acquisition.  
Survey images showing the position of voxel of interest (VOI) and centre of the 
31
P coil.  
 
The standard phosphorus spectroscopy sequence provided by the manufacturer was used. It 
was based on hyperbolic secant pulses for slice selective inversion and adiabatic half 
passage RF pulse for non-selective excitation. In contrast to the standard procedure manual 
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fine adjustment of centre frequency (F0) was performed if the automatic F0 determination 
was not correct in order to ensure the correct voxel position. In contrast to the default 
iterative or FASTMAP (Fast Automatic Shimming Technique by Mapping Along 
Projections) based shimming algorithm, which was based on the selected spectroscopy 
VOI, an image guided shim volume was selected that included the entire myocardium. 
 
 
Figure 13: 3 T Phillips Achieva MRI scanner. 
 
A short axis cine scan was acquired to calculate the trigger delay for ECG triggering 
and check quality of shimming and F0 determination. The trigger delay was calculated 
such that the spectra were acquired in the diastolic period. The 3-D voxel of acquisition 
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was planned to include most of the septum and apex of the heart. Care was taken to 
minimize blood contamination from the right ventricle (RV) as much as possible. The 
voxel size was kept constant at 89.54 ml (44 x 55 x 37 mm
3
) so that comparisons could 
be made between different subjects and scans. 
 
 
Figure 14: Transmitter and receiver 
31
P surface coil.  
 
Initially, 
1
H spectra were acquired from the same voxel without water suppression and 
repetition time of 2000 ms (total scan time of 16 sec). This helped to ensure adequate 
shim quality and correct F0 determination. F0 could be manually adjusted if necessary. 
Following this the 
31
 P spectra were acquired with a repetition time of 10000 ms, 136 
averages and 512 samples. A repetition time of 10000 ms was found to be optimal to 
 
 
14 cm 
31
P surface coil  
Tuning rods 
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adequately reduce saturation effects without increasing the scan time greatly. The 
spectral acquisition was ECG gated and the trigger delay was set to acquire spectra 
mainly in diastole. The trigger delay was measured by subtracting 250-300 from the 
total length of the cardiac cycle which allowed 250-300 msec of the cardiac cycle left 
for spectral acquisition (acquisition time is 170 msec). The total scan time was 23 
minutes.  
 
Increased chemical shift artefacts are present at 3T. In order to minimise this, slice 
selective inversion for ISIS encoding was based on adiabatic hyperbolic secant pulses, 
which achieved a pulse bandwidth between 1300 Hz (at a distance of 9 cm from the 
surface coil) to 2000 Hz (at a distance of 3 cm from the surface coil). This corresponds 
to a chemical shift displacement of 6-10% for the investigated metabolites PCr and 
gamma-ATP for volumes of interest that were between 3 and 9 cm away from the coil. 
When subjects where scanned the distance from the coil to the ROI averaged about 
7.5cm and no subjects were beyond 9.0 cm. Therefore all subjects would have a 
chemical shift displacement less than 10% which is acceptable. 
 
MRS Analysis 
The spectra were analysed and quantified on jMRUI (java-based Magnetic Resonance 
User Interface) software using AMARES a time domain fitting program 
161
. Post-
processing was performed with 15Hz Gaussian line broadening and Fourier 
transformation. Phase correction was performed with PCr peak as the reference peak. 
Quantification was performed with AMARES using a prior knowledge file to preselect 
the peaks. The concentrations of PCr, ATP and 2, 3-Diphosphoglycerate (2, 3-DPG) 
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were calculated as the area under the peaks. Cramer Rao lower bounds 
162
 were then 
calculated. PCr/ATP ratio was determined after correcting the ATP peak for blood 
contamination as described previously 
163
.  
 
Radionuclide Ventriculography 
 
Left ventricular EF and diastolic filling were assessed by radionuclide ventriculography 
using a gamma camera (Olivetti Modulo-M-200ESL, Figure 15) at rest and during graded 
semi erect exercise on a cycle ergometer (Lode B.V medical technology, Groningen, 
Netherlands, Figure 15),  as previously described by our group 
15
.    
 
Ten minutes after an intravenous injection of 0.03 mg/kg stannous pyrophosphate, 5 mL of 
blood was drawn into a heparinised syringe and incubated for 10 minutes with 925 MBq 
(25 mCi) of 99mTc pertechnetate before reinjection. Studies were acquired on a small-
field-of-view gamma camera fitted with a low-energy, general-purpose, parallel-hole 
collimator and interfaced to a dedicated minicomputer. With the patient on the cycle ergo 
meter, the detector was adjusted for the left anterior oblique view with the best ventricular 
separation and 10° to 15° of caudal tilt. A 20% tolerance window was set about the 
patient's heart rate, and each RR interval was divided into 28 equal frames throughout. A 
constant number of frames per RR interval ensure constant temporal resolution during 
diastole at all heart rates. 
 
Data from each beat were acquired into a memory buffer in a 64 x 64 "word" matrix and if 
accepted, were reformatted with two-thirds forward, one-third backward gating.  
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Figure 15: Radionuclide Ventriculography equipment.  
Gamma camera (Olivetti Modulo-M-200ESL) machine and cycle ergometer (Lode B.V medical 
technology, Groningen, Netherlands). 
 
Three minutes of data were acquired at rest and at each level of exercise after a 1 minute 
period for stabilisation of heart rate at the commencement of each stage. Exercise was 
performed at 20%, 35% and 50% workloads of heart rate reserve. The composite cycle 
derived from each stage was spatially and temporally filtered. Left ventricular counts in 
each frame were determined by a semi automated edge-detection algorithm. Data were 
analysed using LinkMedical MAPS software, Sun Microsystems. Peak left ventricular 
Cycle 
ergometer 
Gamma 
Camera head 
Gamma 
Camera  
 76 
filling rate in terms of end-diastolic volumes per second (EDV/s) and TTPF in 
milliseconds after end systole were calculated from the second derivative of the diastolic 
activity-time curve (Figure 16). The validity of these radionuclide measures of diastolic 
filling at high heart rates has been established previously (21; 22). 
 
 
 
Figure 16: Example of diastolic activity-time curve from radionuclide 
ventriculography.  
 
Diastolic activity-time curve 
LV RV 
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Rest and exercise systolic (SBP) and diastolic blood pressure (DBP) were determined 
by cuff sphygmomanometry. Pulse pressure (PP) was calculated as the difference 
between SBP and DBP and mean arterial pressure as (2*DBP + SBP)/3. End-systolic 
pressure (ESP) approximated by (2*SBP + DBP)/3. All gated blood pool scan-derived 
volumes were normalized to body surface area, yielding their respective indexes: end-
diastolic volume index, end-systolic volume index (ESVI), stroke volume index (SVI), 
and cardiac index. The following indexes were calculated: a) arterial elastance index 
(EaI) = ESP/SVI; b) LV systolic elastance index (ELVI) = ESP/ESVI and c) arterial-
ventricular coupling index (VVC) = EaI/ELVI = (1/EF) – 1. VVC ratio is independent 
of BP measurements and is therefore relatively accurate. 
 
Near Infra Red Spectrophotometry (NIRS) 
NIRS is a non-invasive optical technique that is increasingly used to assess changes in 
tissue oxygenation in skeletal muscle 
164
. This technique is based upon the principle that 
NIRS light easily penetrates skeletal muscle, where it is absorbed by the iron or copper 
content of haemoglobin and myoglobin 
165
.  The majority of NIRS light absorption is due 
to the presence of haemoglobin in the small arterioles, capillaries, and venules of the 
microcirculation 
164
. These features have led to growing interest in the use of NIRS as a 
non-invasive technique to measure changes in muscle oxygenation and blood flow at rest 
and during both submaximal and maximal exercise.   
 
Subjects were investigated in the overnight fasted state. The hair was removed from the 
forearm of participants using a disposable shaver and the skin thickness was measured 
using skin callipers.  Skeletal muscle oxygenated haemoglobin concentration [Oxy-Hb], 
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deoxygenated haemoglobin concentration [Deoxy-Hb] and total haemoglobin 
concentration [HbT] were measured with the OxiplexTS near infrared tissue oximeter (ISS 
Inc., Champaign, IL, USA), Figure 17 .  
 
 This is a frequency domain multi-distance NIRS using 4 laser-diode light sources at two 
wavelengths (692 and 834 nm) and one detector.  The NIRS probe used had source-
detector distances of 3.0 - 4.4.cm to limit the contribution of skin and subcutaneous non-
muscle tissue and was placed over the brachioradialis muscle. The absorbances measured 
represent the sum of haemoglobin in the microvasculature and myoglobin in the myocytes. 
 
 
Figure 17: NIRS Experiment Setting.  
 
BP 
Cuff 
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Oximeter 
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NIRS exploits the difference in optical absorption spectra between the [HbT] and [Deoxy-
Hb]. At a wavelength of 834 nm, [Oxy-Hb] and [Deoxy-Hb] exhibit similar absorption 
coefficients. Therefore, absorption of light at this wavelength is proportional to [HbT] in 
the muscle under examination. At a wavelength of 692 nm, absorption is primarily by the 
deoxygenated Hb. Changes in light absorption at 692 nm provide assessment of changes in 
[Deoxy-Hb]. The difference between absorption at 834 and 692 nm gives the [Oxy-Hb].   
 
A blood pressure cuff was applied around the proximal part of the arm as described 
previously 
166
.  The experiment involved continuous measurements of [Oxy-Hb], [Deoxy-
Hb] and [HbT] at rest for 2 minutes.  Then the cuff was inflated to 220 mm Hg for 1 
minute, to induce forearm arterial occlusion. [Oxy-Hb], [Deoxy-Hb] and [HbT] were again 
recorded continuously during the 1 minute forearm arterial occlusion (Figure 18).  
 
The resting muscle oxygen consumption rate was determined by the rate of decline of the 
difference between [Oxy-Hb] and [Deoxy-Hb] during occlusion and was then expressed 
per 100 gram of forearm muscle tissue. The conversion of oxygen consumption rate to ml 
O2/min/100g was determined as previously described 
166, 167
.   
 
Initially, the oxygen consumption NIRS value (µmol/litre/s) was converted into minutes.   
1.04 kg/L was used for muscle density to convert 1 litre to 100 g of skeletal muscle. 1 mole 
of Hb carries 4 moles of O2.  Then, 1 mole of gas was converted into 1 litre with value of 1 
mole gas = 22.4 L standard temperature and pressure, dry (STPD) conditions.  Oxygen 
saturation was calculated from the ratio between [Oxy-Hb] and [HbT]. 
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Figure 18: NIRS measurement of oxygen consumption.   
This graph shows continuous NIRS measurements at rest, during 1 minute arterial occlusion and 
during recovery in a health subject.  The resting skeletal muscle oxygen consumption rate was 
determined by the rate of decline of the difference between [Oxy-Hb] and [Deoxy-Hb] during 
arterial occlusion.  A represents the start of arterial occlusion whereas B represents the end of 
arterial occlusion. 
 
Symptomatic status assessment 
We used the New York Heart Association (NYHA) class and Minnesota living with 
heart failure (MLHF) questionnaire to assess symptoms.  
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NYHA functional classification:  
Symptom status was determined according to NYHA functional classification as shown 
in Table 3.  
  
Class Patient Symptoms 
Class I   (Mild) No limitation of physical activity.  
Class II  (Mild) Slight limitation of physical activity.  
Class III (Moderate) Marked limitation of physical activity.  
Class IV  (Severe) Unable to carry out any physical activity 
without discomfort.  
Table 3: NYHA functional classification.  
 
 
 
Minnesota Living with heart failure (MLHF) questionnaire 
 
Symptom status was determined by asking patients to complete MLHF questionnaire, 
Figure 19. 
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Figure 19: MLHF questionnaire. 
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CHAPTER 4: REDUCED PERIPHERAL METABOLIC 
RATE IN PATIENTS WITH CHF– A STUDY USING NEAR 
INFRARED SPECTROPHOTOMETER (NIRS) 
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Abstract 
 
Background: We used Near Infrared Spectrophotometer (NIRS) during arterial occlusion 
to measure resting skeletal muscle oxygen consumption in CHF patients and to compare it 
with that in age-matched HVs. 
 
Methods: Fifteen CHF patients (ten males) and eleven HVs (six males) had 
echocardiographic evaluation followed by measurement of the oxygen consumption of the 
brachioradialis muscle using NIRS. This involved continuous measurement of the [Oxy-
Hb] and [Deoxy-Hb] with an Oxiplex TS NIRS probe first under basal overnight fasted 
resting conditions followed by 1 minute of forearm arterial occlusion. A linear decline was 
observed in [Oxy-Hb-Deoxy-Hb] during the arterial occlusion and the oxygen 
consumption rate was calculated from the initial slope observed. 
 
Results: CHF patients were 59 ± 2.8 years old with LVEF 31% ± 2.2 and the HVs were 52 
± 4.8 years old with LVEF 62% ± 2.5. The resting muscle oxygen consumption rate was 
significantly reduced in CHF patients versus HVs (0.04 ± 0.01 mlO2/min/100g versus 0.07 
± 0.01 mlO2/min/100g) p < 0.005. 
 
Conclusions: There is a significant reduction in resting oxygen consumption per gram of 
tissue in skeletal muscle of patients with CHF.   
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Introduction 
CHF is a common condition and associated with considerable morbidity and mortality 
168
. 
Clinical features include muscle weakness, general fatigue and dyspnoea 
169, 170
.  It is clear 
that central haemodynamics correlate poorly with exercise capacity in CHF 
170
.  Therefore, 
attention has been focused on peripheral factors such as intrinsic skeletal muscle 
abnormalities and skeletal muscle underperfusion.  Several studies in patients 
171-176
 and 
animal models of CHF 
177-182
 have described skeletal muscle histological abnormalities, 
including fibre-type transformation toward faster phenotype, fibre atrophy, and reduced 
oxidative enzyme activities.  PCr and creatine kinase (CK) are involved in the fine 
regulation between energy production and energy utilization in muscle cells 
38, 52, 183
.  
31
P 
Magnetic Resonance Spectroscopy (MRS) has revealed a decreased content of 
mitochondrial CK in skeletal muscle of patients with CHF.  However, whether these 
skeletal muscle abnormalities result in reduced peripheral oxygen consumption has never 
been directly assessed. The goal of the present study was therefore to examine whether 
skeletal muscle oxygen consumption is reduced in CHF patients as compared to age 
matched HVs. 
  
Resting skeletal muscle oxygen consumption is the ultimate measure of resting muscle 
metabolic rate, and is affected by environmental temperature, body temperature, the 
microvascular blood flow  and nutrition 
184
.  In the absence of blood flow the oxygen 
content of the tissue diminishes as oxygen is consumed by the mitochondria.  Therefore 
oxygen consumption can be determined by measuring the decline in oxygen saturation of 
haemoglobin and myoglobin following total arterial occlusion.  Assuming the duration of 
occlusion is insufficient to cause a significant shift to anaerobic glycolysis, this will be a 
 86 
reliable indicator of resting oxygen consumption. This work represents a clinical 
application of non-invasive technique to assess and compare resting skeletal muscle 
oxygen consumption in CHF patients and HVs using NIRS. 
 
Methods 
Fifteen CHF patients (ten males) and eleven HVs (six males), who provided written 
informed consent, were included in the study.  Characteristics and treatment of participants 
are shown in Table 4.  The experiment was approved by the local Research Ethics 
Committee at the University of Birmingham, UK and the investigation conforms to the 
principles outlined in the Declaration of Helsinki.   
 
Patient selection 
Inclusion criteria: 
 LVEF ≤ 50%. 
 History of dyspnoea on exertion (NYHA II or III). 
 Sinus rhythm. 
 
Exclusion criteria: 
 Unstable clinical condition in the last 3 months. 
 
Controls selection 
Inclusion criteria: 
 Normal ECG. 
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 Normal Echocardiogram (LVEF ≥ 55%). 
 
Exclusion criteria: 
 History or symptoms of any medical illness. 
 
CHF patients and HVs were matched regarding age, sex and body surface area. All study 
participants had ECG, echocardiographic evaluation and measurement of oxygen 
consumption using NIRS.   
 
Resting Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position 
with a Vivid 7 echocardiographic machine and a 2.5-MHz transducer. Measurements were 
averaged for 3 beats. Resting scans were acquired in standard echocardiographic windows 
for LVEF. LV volumes were obtained by biplane echocardiography, and LVEF was 
derived from a modified Simpson‘s formula. Studies were stored digitally and analyzed 
off-line. 
 
NIRS 
Subjects were investigated in the overnight fasted state. Skeletal muscle [Oxy-Hb], 
[Deoxy-Hb] and [HbT] were measured at rest and during 1 minute forearm arterial 
occlusion (Figure 20). The resting muscle oxygen consumption rate was determined by the 
rate of decline of the difference between [Oxy-Hb] and [Deoxy-Hb] during occlusion and 
was then expressed per 100 gram of forearm muscle tissue.  
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Figure 20: Oxygen Consumption in HVs & CHF patients.   
This graph shows continuous NIRS measurements at rest, during 1 minute arterial occlusion and 
during recovery in HVs (white circle) and CHF patients (black circle).  The resting skeletal muscle 
oxygen consumption rate was determined by the rate of decline of the difference between [Oxy-Hb] 
and [Deoxy-Hb] during arterial occlusion.  A represent the start of arterial occlusion whereas B 
represent the end of arterial occlusion. 
 
Statistics 
Comparison of oxygen consumption in HVs with CHF patients was determined by a 2–
sided Student‘s t-test. Data were analyzed with SPSS 14 for Windows and expressed as 
mean ± standard deviation (SD).  Variances of data sets were determined using F-test.  A 
difference of a p value of < 0.05 was taken to indicate statistical significance.  
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Results 
CHF patients and HVs were well matched with respect to age and gender (Table 4). 
However, LVEF was significantly lower in CHF patients (Table 5). 
 
Parameter  CHF patients  H Vs  P value  
Age (mean ± SD) 59.33 ± 2.82  52 ± 4.8  ns  
Number (male)  15 (10)  11 (6)  ns 
NYHA  II-IV  ……  ……  
Diabetes  3  0  ……  
ACE inhibitors  10  0  ……  
AT2 receptor blockers  4  0  ……  
ß-Blockers  8  0  ……  
Aspirin  6  0  ……  
Diuretics  13  0  ……  
Warfarin  8  0  ……  
Calcium channel blockers  1  0  ……  
Spironolactone  3  0  ……  
Amiodarone  1  0  ……  
Statins  10  0  ……  
Oral Hypoglycemic agents  3  0  ……  
Insulin  1  0  ……  
Table 4: CHF patients and HVs characteristics and treatments - NIRS study.   
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Parameter  CHF patients  H Vs  P value  
BMI (Kg/m
2
) 25.6 ± 4.2 24.9 ± 3.7 ns 
Skin fold thickness (mm)  8.01 ± 3.1 6.5  ± 4.3  ns  
LVEF (%)  31.35  ± 2.15  62.15 ± 2.46  < 0.001  
LVEDV (ml)  162 ± 25  76  ± 4.5  < 0.05 
LVESV (ml)  113  ± 19  29 ± 3  < 0.05 
Stroke Volume (ml)    49 ± 8  47 ± 4  ns  
Resting O2 sat (%) 62.85 ± 1.96  64.18 ± 2.50  ns  
Resting [Hb-T] (μmol)  47.86 ± 4.27  59.66 ± 4.46  < 0.05  
Resting [Oxy-Hb] (μmol) 30.13 ± 2.95  37.68 ± 2.45  < 0.05  
Resting [Deoxy-Hb] (μmol) 17.73 ± 1.68  21.97  ± 2.88  ns  
 
Table 5 : Baseline investigations of CHF patients and HVs – NIRS study.   
 
Resting NIRS measurements showed no significant difference in resting oxygen saturation 
in CHF versus HVs (62.85 ± 1.96 versus 64.18 ± 2.50 %, p=0.67).  However the resting 
[HbT] was significantly lower in CHF patients (47.86 ± 4.27 μmol) versus HVs (59.66 ± 
4.46 μmol, p < 0.05).  The [Oxy-Hb] was also significantly lower in CHF patients (30.13 ± 
2.95 vs 37.68 ± 2.45 μmol, p < 0.05). There was a non-significant trend towards a lower 
[Deoxy-Hb], probably as a result of lower [HbT] (17.73 ± 1.68 vs 21.97 ± 2.88 μmol, p = 
0.094) (Table 5).  Oxygen consumption at rest in CHF patients was significantly reduced 
versus HVs (0.04 ± 0.01 mlO2/min/100g versus 0.07 ± 0.01 mlO2/min/100g) p < 0.005.  
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There were no correlations between oxygen consumption and LVEF in patients with CHF 
(r = 0.09, p=0.74) (Figure 21).    
 
 
 
Figure 21: Correlation between skeletal muscle oxygen consumption and LVEF in 
CHF patients.   
There is no correlation between peripheral oxygen consumption, as expressed in ml/100g/min, and 
LVEF in patients with CHF.  
 
Measurements of oxygen consumption correlated positively with [Oxy-Hb] (r = 0.59, p = 
0.001), [Deoxy-Hb] (r = 0.71, p < 0.001) and [HbT] (r = 0.73, p < 0.001) (Figure 22 A, B 
and C).  However, there was no significant correlation between oxygen consumption and 
oxygen saturation (r = 0.28, p = 0.17) (Figure 22D).  
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Discussion 
In the present study, we have used a non-invasive tool (NIRS) to measure peripheral 
oxygen consumption in CHF patients and age matched HVs. Whilst a reduction in peak 
oxygen consumption during exercise is a hallmark of heart failure, our finding of reduced 
resting peripheral oxygen consumption is to the best of our knowledge novel.  Both central 
and skeletal muscle factors play a role in exercise limitation in CHF, though the relative 
importance of each has been controversial 
185, 186
. 
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Figure 22: Correlation between skeletal muscle oxygen consumption and resting 
NIRS measurements.   
There were positive correlation between peripheral oxygen consumption and resting [Oxy-Hb] 
(graph A), [Deoxy-Hb] (graph B) and [HbT] (graph C).  However, there was no significant 
correlation between peripheral oxygen consumption and resting oxygen saturation (graph D). 
 93 
Skeletal muscle underperfusion is a recognized feature in CHF patients 
187
. This leads to a 
reduction in oxygen supply to skeletal muscle that might result in adaptation of the skeletal 
muscle to consume less oxygen at rest. NIRS measurement of [Oxy-Hb] and [HbT] had 
been used as a surrogate measurement of skeletal muscle blood flow 
187, 188
.  Our resting 
data of [Oxy-Hb] and [HbT] were reduced at rest in CHF patients as compared to age 
matched HVs (Table 5), which is in agreement with Wilson JR and co-workers 
187
. 
Interestingly, Massie and co-workers 
189
 showed no relationship between skeletal muscle 
blood flow and the metabolic findings in CHF patients. However, it is important to note 
that we measured skeletal muscle oxygen consumption under conditions of temporary 
circulatory occlusion therefore reduction in oxygen delivery cannot be the direct cause of 
the observed reduction in skeletal muscle oxygen consumption. Chronic skeletal muscle 
hypoperfusion may nevertheless induce adaptive changes in skeletal muscle function that 
are responsible for the reduced oxygen consumption.  Furthermore, it is important to note 
that the oxygen consumption measurements are expressed per 100 mls forearm tissue 
therefore these findings cannot be explained in terms of a reduced skeletal muscle mass in 
heart failure patients. The mechanisms that may lead to this reduction in resting oxygen 
consumption are discussed below. 
 
Possible mechanisms underlying reduced skeletal muscle oxygen 
consumption in CHF patients 
 
Heart failure is associated with altered metabolism within the skeletal muscle 
190
 with 
reduction in mitochondrial density and oxidative enzymes resulting in reduced aerobic 
capacity 
171, 191, 192
.  Evidence of a reduction in mitochondrial density originates from 
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studies showing that CHF patients had increased PCr breakdown, intracellular acidosis 
193
, 
decreased rate of ATP resynthesis during exercise and recovery 
193, 194
 and activity of 
selected oxidative enzymes 
174, 175
.  Furthermore, other studies showed that abnormal 
skeletal muscle metabolism contributes to the reduced functional capacity in CHF patients 
193-195
.  Further studies are required to examine the contribution of these mitochondrial 
factors to the observed reduction in skeletal muscle oxygen consumption in CHF patients. 
 
Previous reported studies have shown that skeletal muscle energetic status at rest is not 
significantly impaired in heart failure, in contrast there is accelerated PCr depletion and 
slower recovery of PCr following exercise 
196
.  These indicate a reduced ability to generate 
ATP during the increased demands associated with exercise.  Accordingly our observations 
can only be explained either by a reduced metabolic rate in skeletal muscle (i.e. a reduced 
resting requirement for ATP production) or by an increase in metabolic efficiency (i.e. an 
increase in ATP production per unit oxygen consumption). The former paradigm would 
imply a situation analogous to ‗hibernation‘ seen in cardiac muscle in which repetitive 
myocardial stunning induces a downregulation of basal metabolic processes. Heart muscle 
contractile function can be recruited to hibernating myocardium by the infusion of low 
dose dobutamine but further increments in dobutamine infusion rate result in a loss of 
contractile function again 
197
. In the same way it is possible to conceive of a reduction in 
basal metabolic rate with a capacity to upregulate metabolism during low level exercise but 
rapid fatigue at higher exercise loads. The second paradigm (increased metabolic 
efficiency) might theoretically be explained by a change in substrate utilization. Skeletal 
muscle is capable of using various sources to generate energy such as carbohydrates, fats 
(including ketones derived from fats) and proteins. The oxidation of glucose generates 
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approximately 12% more ATP per unit oxygen consumption than the oxidation of fats 
38, 52, 
183
. At rest in the fasting state skeletal muscle metabolizes principally free fatty acids 
(FFAs) and they are also the main form of substrate during low to medium intensity 
exercise 
198
. However, Sidossis and colleagues showed that FFAs oxidation is limited 
during high-intensity exercise, which suggest a shift to an energy efficient substrate such as 
glucose 
198
.  Theoretically a shift towards greater glucose utilization might result in greater 
metabolic efficiency, which leads to less oxygen consumed to generate same amount of 
ATP as compared to FFAs. However, this shift could not on its own explain the magnitude 
of the difference in oxygen consumption that we observed. 
 
Skeletal muscle atrophy and fibrosis  
In the present study, both CHF and HVs groups had comparable body mass index (Table 
5).  There was an insignificant small increase in the forearm skin thickness in CHF patients 
as compared to HVs (8.01 mm ± 3.10 vs. 6.50 mm ± 4.30, respectively).  However, the 
NIRS probe used in this study had source-detector distances of 30-44 mm to limit the 
contribution of skin and subcutaneous non-muscle tissue.  Skeletal muscle atrophy has 
been observed in patients with CHF 
194, 199
, which may result  from different mechanisms 
such as inactivity, inflammation, apoptosis and an imbalance in catabolic/anabolic 
processes 
200
. Our measurement of oxygen consumption was expressed as per 100 gram of 
forearm muscle tissue.  Therefore, skeletal muscle atrophy and increased interstitial fat 
content and fibrosis in CHF patients may contribute to the reduction in oxygen 
consumption, but seems unlikely to explain the magnitude of the difference. 
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CHAPTER 5:  LEFT VENTRICULAR STRAIN AND 
UNTWIST IN HCM: RELATION TO EXERCISE 
CAPACITY 
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Abstract 
Background: HCM is often associated with reduced exercise capacity.  This study 
examined the importance of left ventricular strain, twist and untwist as predictors of 
exercise capacity in HCM patients.  
 
Method: 56 HCM patients (31 male and mean age of 52 years) and 43 age and gender 
matched controls were enrolled.  We measured peak oxygen consumption (peak VO2) 
and acquired standard echocardiographic images in all participants.  2-D speckle 
tracking was applied to measure rotation, twist, untwist rates, strain and strain rate.  
 
Results: HCM patients exhibited marked exercise limitation compared to controls (peak 
VO2 23.28 ± 6.31 vs 37.70 ± 7.99 ml/kg/min, p < 0.0001).  LVEF in HCM patients and 
controls was similar (62.76 ± 9.05 % vs 62.48 ± 5.82 %, p =0.86).  Longitudinal, radial 
and circumferential strain and strain rate were all significantly reduced in HCM patients 
compared to controls. There was a significant delay in 25 % of untwist in HCM 
compared to controls.  Both systolic and diastolic apical rotation rates were lower in 
HCM patients. Longitudinal systolic and diastolic strain rate correlated significantly 
with peak VO2 (r = -0.34, p = 0.01 and r = 0.36, p = 0.006 respectively). 25% untwist 
correlated significantly with peak VO2 (r = 0.36, p = 0.006). 
 
 98 
Conclusion: There are widespread abnormalities of both systolic and diastolic function 
such as strain and untwist in HCM patients and that these abnormalities are significant 
determinants of exercise capacity.   
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Introduction 
Patients with HCM often complain
 
of breathlessness and/or fatigue and most have 
reduced exercise capacity 
15
.  HCM patients typically exhibit diastolic dysfunction, 
which is thought to contribute significantly to the genesis of breathlessness in these 
patients.  Active relaxation is slowed and filling rate is typically diminished at rest in 
HCM patients 
14
.  Furthermore, our group previously showed that there is frequently a 
failure of the normal increase in rate of active relaxation (as measured by TTPF) on 
exercise, indeed in some patient‘s active relaxation paradoxically slowed on exertion 15.   
 
Resting echocardiographic Doppler
 
parameters of LV filling have been used to measure 
diastolic
 
function 
201
.  However, these parameters are dependent on loading conditions.  
The LV twists during systole as a result of counter clockwise rotation of the apex and 
clockwise rotation of the base with corresponding untwisting during diastole.  The 
resulting untwisting may represent a useful marker of diastolic function, which is 
largely independent of loading conditions 
202, 203
.  The velocity of
 
LV untwisting has 
been correlated with invasive
 
measurements of LV relaxation under a variety
 
of loading 
and inotropic conditions in animal models.  Dong and colleagues confirmed that
 
LV 
untwisting is a measure of LV relaxation which is independent
 
of preload as reflected in 
left atrial pressure 
204
.   
 
The development of STE has allowed LV strain, twisting and untwisting rates to be 
measured relatively easily with reasonably high temporal resolution 
157
. In this study, 
we used STE to measure LV strain, strain rate, twist and untwist rates in HCM patients 
and controls and we sought to assess their relationship with exercise capacity.  
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Methods 
56 HCM patients and 43 age and gender matched controls were included in this study 
all of whom provided written informed consent.  The study was approved by the local 
ethics committee and the investigations conform to the principles outlined in the 
Declaration of Helsinki.  All study participants had ECG, echocardiogram and 
cardiopulmonary exercise test. 
 
Patients selection 
Inclusion criteria: 
 Aged 18 years or above. 
 Fulfilled conventional echocardiographic criteria for the diagnosis of HCM 
       (LV wall  thickness greater than 1.5 cm in the absence of another cause for  
       hypertrophy and  without cavity dilatation) 
205, 206
. 
 Sinus rhythm. 
 
Exclusion criteria: 
 A resting or provocable LVOTO gradient > 30mmHg. Those patients were  
       excluded because LVOTO is an important cause of symptoms and exercise  
       limitation. 
 
Controls selection 
Inclusion criteria: 
 Normal ECG. 
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 Normal Echocardiogram (LVEF ≥ 55%). 
 
Exclusion criteria: 
 History or symptoms of any medical illness.  
 
Cardiopulmonary Exercise Test 
This was performed using a Schiller CS-200 Ergo-Spiro exercise machine which was 
calibrated before every study. Subjects underwent spirometry and this was followed by 
symptom-limited erect treadmill exercise testing. Participants were encouraged to 
exercise to exhaustion with a minimal requirement of RER > 1.  Peak oxygen 
consumption (peak VO2) was defined as the highest
 
VO2 achieved during exercise and 
was expressed in ml/min/kg. 
 
 
 
Resting Echocardiography 
LV volumes were obtained by biplane echocardiography, and LVEF was derived from a 
modified Simpson‘s formula 150.  A pulse wave Doppler sample volume was placed at 
the mitral valve tips to record 3 cardiac cycles.  Mitral annulus velocities [PW-TDI] 
were recorded from basal anterolateral and basal inferoseptal segment in apical 4-
chamber view.  LA volumes were measured by area length method from apical 2 and 4 
chambers as previously described 
150
 and indexed to body surface area to derive LA 
volume index (LAVI).  LV mass was measured by area length method and indexed to 
body surface area to derive LV mass index as previously described 
151
. The greatest 
thickness measured in the LV wall at
 
any short axis parasternal view was considered to 
represent maximal
 
LV wall thickness (MWT) in HCM patients 
13
. 
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Speckle Tacking Echocardiography (STE) 
LV peak strain and strain rate in each view were calculated with the use of the entire 
length of the LV myocardium.  The basal and apical LV global rot and rot-r STE data 
were measured from basal and apical short axis view respectively and were then 
exported to a spreadsheet program (Excel 2003, Microsoft Corp, Seattle, Washington) 
and then exported to DPlot Graph Software (2001-2008 by HydeSoft Computing, Inc) 
to calculate LV twisting and untwisting rate 
157
.   
 
Statistics 
Data were analyzed using SPSS ver. 15.0 for Window and Microsoft Office Excel 2007, 
and expressed as mean ± standard deviation (SD).  Comparison of variables between 
HCM patients and controls were by unpaired Student‘s t-test (2-tail) if variables were 
normally distributed and the Mann-Whitney U-test if the data were non-normally 
distributed.  A difference of p < 0.05 was taken to indicate statistical significance. 
Pearson‘s correlation coefficient was used to examine correlations between exercise 
capacity and echocardiographic parameters in HCM patients.   
 
Results 
The clinical characteristics and cardiopulmonary exercise test results of HCM patients 
and controls are shown in Table 6.  Both groups were well matched with respect to age 
and gender.  HCM patients exhibited marked exercise limitation as compared to 
controls whereas mean EF was comparable in both groups.  Heart rate was lower in the 
HCM group, as compared to controls, due to rate limiting medication (beta blockers 
or/and calcium channel blockers).    
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Conventional Echocardiographic Measurements 
Standard, Doppler and PW-TDI echocardiographic findings of HCM and controls 
groups are listed in Table 7.  Transmitral Doppler measurements showed no significant 
difference in peak E and A, and E/A ratio in HCM versus controls (Table 7).  However, 
PW-TDI measurements of Sm, Em, Am and E/Em of the inferoseptal, anterolateral and 
average basal segments were significantly lower in HCM patients compared to controls 
(Table 7).   
 
Two Dimensional STE Measurements 
STE measurements of strain and strain rate are shown in Table 8. Longitudinal strain 
(SL) and strain rate (SrL) during both systole and diastole were all significantly reduced 
in HCM patients as compared to controls.  Similarly, radial strain (SR) and strain rate 
(SrR) were also significantly lower in HCM patients than in controls.  Circumferential 
strain (SC) and diastolic strain rate (SrC) were also significantly lower in HCM patients 
as compared to controls. There was a non-significant trend to lower systolic 
circumferential strain rate (SrC) in HCM patients compared to controls. 
 
Twist and Untwist Rate 
STE measurements of LV rotation, twist and untwist in both groups are shown in Table 
9 . There was no significant difference in the LV ability to twist in systole and untwist 
in diastole between HCM and controls. However, 25% untwist was significantly 
delayed in HCM versus controls. Unlike the base, there was a significant reduction in 
apical rotation rates during systole and diastole in HCM patients as compared to 
controls.  
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Parameter  HCM  Controls  P value  
 
Age [years] 
 
52 ± 11 
 
51 ± 16 
 
0.74 
Number (Female)  56 (16)  43 (12)  0.64 
Heart Rate [bpm] 68.58 ± 13.19  80.47 ± 15.71  0.0002* 
Systolic BP [mm Hg] 125.67 ± 19.42 124.51 ± 19.8 0.78 
Diastolic BP [mm Hg] 77.58 ± 10.77 78.17 ± 10.72   0.80 
Peak VO2 [ml/kg/min]  23.28 ± 6.31  37.70 ± 7.99  < 0.0001* 
Drug therapy – no. (%)    
     Diuretic 10 (18) 0 - 
     ACE inhibitor 6 (11) 0 - 
     ARB 1 (2) 0 - 
     Beta-blocker 17 (31) 0 - 
     Calcium channel blocker 26 (47) 0 - 
     Aspirin 13 (24) 0 - 
     Warfarin 5 (9) 0 - 
     Nitrate 2 (4) 0 - 
     Statin 15 (27) 0 - 
Table 6: The clinical characteristics and cardiopulmonary exercise test results of 
HCM patients and controls – STE study.  
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Parameter  
 
HCM  
 
Controls  
 
P value  
 
EF Biplane (%)  
 
62.76 ± 9.05  
 
62.48  ± 5.82  
 
0.86 
Biplane LA Volume (ml) 72.69 ± 29.22 35.09 ± 9.83 < 0.0001* 
LA Volume Index (ml/m
2
) 33.92 ± 14.62 11.76 ± 10.17 < 0.0001* 
LV Mass Index (g/m
2
) 181.92 ± 84.09 71.67 ± 23.82 < 0.0001* 
MV E (m/s) 0.69 ± 0.16 0.67 ± 0.15 0.49 
MV A (m/s) 0.64 ± 0.19 0.59 ± 0.15 0.17 
MV E/A 1.18 ± 0.48 1.20 ± 0.38  0.83 
MV Dec Time (ms) 231.12 ± 71.66  260.10  ± 68.24  0.06 
Antlat Sm (cm/s) 0.06 ± 0.02  0.10 ± 0.03 < 0.0001* 
Antlat Em (cm/s) 0.08 ± 0.03   0.11 ± 0.04 < 0.0001* 
Antlat Am (cm/s) 0.07 ± 0.03    0.09 ± 0.02 < 0.0001* 
Infsep Sm (cm/s) 0.06 ± 0.02    0.08 ± 0.02 0.0001* 
Infsep Em (cm/s) 0.05 ± 0.02   0.08 ± 0.03   < 0.0001* 
Infsep Am (cm/s) 0.07 ± 0.02   0.09 ± 0.02 < 0.0001* 
Average Sm (cm/s) 
Average Em (cm/s) 
0.06 ± 0.02    
0.06 ± 0.02   
0.09 ± 0.02 
0.09 ± 0.04 
< 0.0001* 
< 0.0001* 
E/Em antlat 9.70 ± 3.86   6.71 ± 2.35 0.0001* 
E/Em infsep 17.05 ± 7.38    9.64 ± 3.34   < 0.0001* 
E/Em average 11.81 ±  4.28 8.04 ± 2.92   < 0.0001* 
Table 7: Standard, Doppler and PW-TDI Echocardiographic characteristics of 
HCM vs controls – STE study.  
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Parameter 
 
HCM  
 
Controls  
 
P value  
 
Longitudinal 
 
 
 
 
 
 
      SL Peak S (%) -12.74 ± 4.21 -18.38 ± 2.99 < 0.0001* 
      SrL Peak S (1/s) -0.92 ± 0.25 -1.14 ± 0.2 < 0.0001* 
      SrL Peak E (1/s) 0.94 ± 0.35 1.33 ± 0.3 < 0.0001* 
      SrL Peak A (1/s) 0.78 ± 0.28 
 
1.07 ± 0.29 
 
< 0.0001* 
Radial    
      SR Peak S (%) 17.52 ± 7.86 29.63 ± 13.26 < 0.0001* 
      SrR Peak S (1/s) 1.22 ± 0.34 1.39 ± 0.34 0.02* 
      SrR Peak E (1/s) -1.0 ± 0.39 -1.46 ± 0.52 < 0.0001* 
      SrR Peak A (1/s) -0.77 ± 0.38 -1.09 ± 0.61 < 0.01* 
 
Circumferential 
   
      SC Peak S (%) -16.50 ± 4.29 -19.99 ± 5.53 < 0.001* 
      SrC Peak S (1/s) -1.4 ± 0.35 -1.54 ± 0.34 0.05 
      SrC Peak E (1/s) 1.34 ± 0.42 1.8 ± 0.65 < 0.001* 
      SrC Peak A (1/s) 0.87 ± 0.34 1.09± 0.47 0.02* 
Table 8: STE results of longitudinal, radial & circumferential strain and strain 
rates in HCM patients vs controls.  
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Predictors of Exercise Capacity  
In HCM patients, exercise capacity (peak VO2) was independent of LV mass index (r = 
0.01, p = 0.97, Figure 23A), MWT (r = 0.04, p = 0.8, Figure 23B) or LA volume index 
(r = - 0.08, p = 0.6, Figure 23C). However, it significantly correlated with the following 
STE parameters:  longitudinal strain rate (SrL) during systole (peak S) (r = -0.34, p = 
0.01, Figure 24A), during early diastole (peak E) (r = 0.36, p = 0.006, Figure 24B) and 
during late diastole (peak A) (r = 0.31, p = 0.02, Figure 24C), and it also correlated with 
25% untwist (r = 0.36, p = 0.006, Figure 24D).   
 
Discussion 
In this study we assessed myocardial strain using an ultrasound speckle tracking 
technique that avoids the angle-dependency of Doppler-based techniques.  Longitudinal, 
radial and circumferential strain and strain rates, twist and untwist rates were measured 
in HCM patients and in age and gender matched controls. Whilst HCM patients 
typically exhibit hyperdynamic systolic function as assessed by conventional 
echocardiography, our STE findings of reduced longitudinal strain rate and delayed 
25% untwist as significant predictors of exercise capacity are to the best of our 
knowledge novel.  
 
STE tracks characteristic speckle patterns created by interference of ultrasound beams 
in the myocardium which is based on grayscale B-mode images, and is angle 
independent 
152
.   
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Parameter 
 
HCM  
 
Controls  
 
P value  
 
Apical Rot and Rot-R 
 
 
 
 
 
 
      Peak Rot (deg)                                                                   7.65 ± 6.90 9.48 ± 5.40 0.18 
      Peak S Rot R (deg/s) 49.77 ± 49.49 74.56 ± 42.25 0.01* 
      Peak E Rot R (deg/s) -41.19 ± 39.14 -72.96 ± 38.00 < 0.001* 
      Peak A Rot R (deg/s) -26.24 ± 33.94 
 
-39.87 ± 27.01 
 
<0.05* 
Basal Rot and Rot-R    
      Peak Rotation (deg)                                                                   -6.25 ± 3.73 -5.80 ± 2.81 0.55 
      Peak S Rotation Rate (deg/s) -57.89 ± 28.94 -61.24 ± 17.82 0.54 
      Peak E Rotation Rate (deg/s) 53.07 ± 25.96 48.88 ± 26.42 0.47 
      Peak S Rotation Rate (deg/s) 42.39 ± 24.52 44.67 ± 20.68 0.65 
 
Twist and Untwist 
   
      Peak Twist (deg) 13.37 ± 7.14 13.69 ± 6.55 0.83 
      25% Untwist (deg) 9.85 ± 5.47 10.27 ± 4.91 0.71 
      Time 25% Untwist (R-R %) 11.34 ± 5.63 7.21 ± 8.01 0.01* 
    
 
Table 9: STE measurement of LV rotation, twist and untwist in HCM and 
controls. 
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Figure 23: Correlation between exercise capacity (peak V02) and (A) LV Mass 
Index, (B) MWT and (C) LV Volume Index. 
 
In humans, measurement of LV long-axis strain by STE correlated well with MRI 
tagging (r=0.87)
207
.   We are now able to characterize myocardial function in greater 
detail breaking down global function into the individual components that make up the 
whole.  This can now be done for both the diastolic phase and systolic phases of 
myocardial function quickly and reproducibly using a relatively new technique of 
speckle tracking. 
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Figure 24: Correlation between exercise capacity (peak V02) and (A) Longitudinal 
strain rate (SrL) Peak S, (B) SrL Peak E, (C) SrL Peak A and (D) 25% Untwist. 
 
Our findings of reduced longitudinal, circumferential and radial strains are in agreement 
with previously published works 
208
. However the clinical relevance of these alterations 
in function has not been previously assessed. 
 
Systolic function in HCM 
The function of the LV is often described as hyperdynamic in HCM. This is based on 
the frequent observation of high normal or supra-normal EF.  In this study, we showed 
that HCM patients had reduced systolic STE-derived longitudinal, circumferential and 
radial strain and strain rates despite normal LVEF.  These results are consistent with 
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TDI-derived data which have shown that systolic long-axis function is reduced in 
patients with HCM 
209
. Carasso and colleagues showed reduced longitudinal but higher 
circumferential STE-derived strain and strain rate in HCM patients compared to 
controls 
210
.  Our findings of reduced circumferential strain are consistent with previous 
tagged MRI studies 
211, 212
.   
 
Diastolic function in HCM 
The majority of HCM patients have some degree of diastolic dysfunction 
213-216
 
independent of symptoms, presence of ventricular outflow tract obstruction, the 
magnitude of hypertrophy, or a combination of these 
12, 209, 214, 217
.  The mechanisms 
responsible for the diastolic dysfunction are probably multifactorial.  The hypertrophy, 
myocyte disarray and fibrosis may increase passive left ventricular stiffness. Several 
studies had shown abnormalities of active relaxation in HCM patients 
218, 219
 and these 
may relate to abnormal calcium handling 
17
, to microvascular myocardial ischaemia and 
mechanical dyssynchrony 
18
, or to impaired myocardial energy utilisation 
19, 38, 52
.  
 
There are several echo measurements that can quantify
 
diastolic dysfunction in HCM 
patient but there remain some controversies about their accuracy. Our data showed no 
significant difference in transmitral Doppler derived parameters between HCM patients 
and controls. However, there were significant abnormalities of other echocardiographic 
measurements of diastolic function (such as LA Volume, LA Volume Index and TDI-
derived indexes) in HCM patients. More importantly, untwist (a marker of diastolic 
function) was significantly delayed in these patients which is in agreement with a 
previous study 
220
.  
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Exercise limitation in HCM 
Traditionally it has been believed that LV diastolic dysfunction is the predominant 
cause of breathlessness and exercise limitation in HCM patients 
15
.  Interestingly, we 
found that markers of both left ventricular systolic and diastolic function significantly 
correlated with exercise capacity.  
 
Our colleagues have previously 
15
 demonstrated that exercise capacity in patients with 
HCM is limited by the failure to increase stroke volume on peak exercise.  Furthermore, 
the normal inverse relationship of TTPF of the LV with increasing heart rate was lost.  
A similar pattern has also been shown in patients with ischaemic heart disease 
221
. The 
mechanism of this limitation of left ventricular filling has not been fully elucidated.  
 
Left ventricular untwist is increasingly being recognized as an important component of 
diastolic function, contributing significantly to suction. Knudtson et al 
222
 have shown 
that myocardial ischaemia impairs untwist.  Untwisting, a recoil phenomenon occurs 
during the isovolumetric relaxation period, tending towards geometric restoration of the 
zero twist point (end diastole) with concurrent maximum left ventricular volume.  Twist 
and untwist rates appear to be closely related.  During systole myocardial deformation 
(twist) results in elastic energy being stored in compressed titin 
223
 and  transmural shear 
between myofibril sheets 
224
.  This energy is spent during early diastole, before the onset 
of left ventricular filling 
225
 which leads to untwisting of the LV that contributes to the 
generation of suction.  The basis of twist and untwist abnormalities in HCM patients is 
possibly due to regional abnormalities of systolic and diastolic function 
226
.  Peak 
ventricular untwist rate has been correlated with the time constant of LV pressure decay 
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and intraventricular pressure gradients, both markers of diastolic function 
227
.  Rovner A 
and colleagues showed a significant improvement in
 
intraventricular pressure gradients 
in patients with obstructive HCM after alcohol ablation 
228
.  Reduced untwist rate may 
lead to impairment in diastolic filling, which becomes more notable with increased heart 
rates 
153
 due to short filling period. Notomi and colleagues showed that greater 
untwisting rate produced an increase in suction during exercise in healthy subjects, 
which is able to fill the ventricle more despite a shorter filling period.  This suggest that 
untwist rate is an important mechanism augmenting LV filling.   
 
The delayed untwist in HCM patients observed in this study may lead to reduced left 
ventricular suction and filling, which will reduce the ability to utilize the Starling 
mechanism, leading to a failure to increase cardiac output, and as a result will limit 
exercise capacity.     
 
In summary, although HCM patients often had normal/supranormal LVEF as measured 
by conventional echocardiography, STE imaging demonstrated a marked impairment of 
both systolic and diastolic LV function and they were both significant determinants of 
exercise capacity.   
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CHAPTER 6: VALIDATION AND REPRODUCIBILITY 
OF HIGH ENERGY PHOSPHATE KINETICS IN THE 
MYOCARDIUM USING 
31
P CARDIAC SPECTROSCOPY 
AT 3 TESLA        
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Abstract 
Background: 
31
P magnetic resonance spectroscopy (MRS) allows measurement of in 
vivo high energy phosphate kinetics in the myocardium. While traditionally 
31
P cardiac 
spectroscopy is performed at 1.5 Tesla, cardiac MRS at higher field strength can 
theoretically increase SNR and spectral resolution therefore improving sensitivity and 
specificity of the cardiac spectra. The reproducibility and feasibility of performing 
cardiac spectroscopy at 3 Tesla is presented here in this study in HVs and patients with 
HCM. 
 
Methods: Cardiac spectroscopy was performed using a Phillips 3T Achieva scanner in 
37 HVs and 26 patients with HCM to test the feasibility of the protocol. To test the 
reproducibility a single volunteer was scanned eight times on separate occasions. A 
single voxel 
31
P MRS was performed using Image Selected In vivo Spectroscopy (ISIS) 
volume localisation.  
 
Results: The mean PCr/Adenosine Triphosphate (PCr/ATP) ratio of the eight 
measurements performed on one individual was 2.11±0.25. Bland Altman plots showed 
a variance of 12% in the measurement of PCr/ATP ratios. The PCr/ATP ratio was 
significantly reduced in HCM patients compared to controls, 1.42 ± 0.51 and 2.11 ± 
0.57, respectively, P<0.0001. (All results are expressed as mean ± standard deviation). 
 
Conclusions: Here we demonstrate that cardiac 
31
P MRS at 3T is a reliable method of 
measuring in vivo high energy phosphate kinetics in the myocardium for clinical studies 
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and diagnostics. Based on our data an impairment of cardiac energetic state in patients 
with HCM is indisputable.   
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Introduction 
Phosphorus Spectroscopy is a non-invasive method of studying cardiac in vivo high 
energy phosphate kinetics 
229
. It allows for determination of PCr, ATP, Adenosine 
Diphosphate (ADP) and inorganic phosphate (Pi) concentrations in the myocardium. 
The concentrations of these substances and the ratio of PCr/ATP are measures of the 
cardiac energetic status.  PCr is an important short-term reserve energy source that 
maintains a high phosphorylation potential under conditions of increased energy 
demand like exercise and ischaemia. The conversion of ADP to ATP by transfer of a 
phosphoryl group from PCr is catalysed by creatine kinase. This reaction occurs 10 
times faster than ATP production via oxidative phosphorylation 
79
.  
 
In patients with mild to moderate heart failure, cardiac ATP flux mediated by creatine 
kinase is reduced by approximately 50% 
230
. Animal and human studies have 
demonstrated that a progressive reduction of the creatine pool is directly related to the 
severity of heart failure 
84
. This is largely due to a decrease in the number of creatine 
transporters at sites of energy production and utilisation 
87
. In normal myocardium two 
thirds of the creatine pool is phosphorylated via creatine kinase reaction to form PCr 
38, 
52, 183
 and the expression and activity of this enzyme is reduced in heart failure 
231, 232
. 
Therefore in heart failure the available PCr is markedly diminished. The depletion of 
PCr occurs to a greater extent compared to ATP resulting in reduced PCr/ATP ratio in 
heart failure as measured by MRS 
85
. Reduced PCr/ATP ratio is associated with 
increased mortality in heart failure patients 
86
. 
31
P cardiac spectroscopy can also be used 
to monitor disease progress in heart failure patients. It has been used as an objective 
marker to show benefits of various treatments such as metabolic modulators 
233
.  
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Reduced PCr/ATP ratio is also seen in other conditions including ischaemic heart 
disease 
234
,  left ventricular hypertrophy secondary to hypertension 
235
, valvular heart 
disease (mitral regurgitation and aortic valve disease) 
85, 86
, diabetes 
236
 and HCM 
34, 237, 
238
. Interestingly, patients with genotypic HCM who do not yet have hypertrophy have a 
similar degree of impairment of cardiac PCr/ATP ratio as do patients with marked 
hypertrophy, implying that the disturbance may be an early feature of the disease and is 
not simply due to the hypertrophy 
32
. 
 
Traditionally cardiac spectroscopy in humans has been performed using 1.5 Tesla 
magnets.  Previous studies in animals 
239
 and humans demonstrated that higher field 
strength such as 3T 
240
 or 4.7T offer higher SNR. The increased sensitivity can be traded 
for either increased spatial resolution or improved quantification precision and hence 
might improve specificity of 
31
P cardiac MRS as a diagnostic tool. Hence it is desirable 
to perform cardiac MRS at 3T MR scanners. However, higher field strength also result 
in inhomogeneities of transmit and receive B1 field along with restrictions of the 
maximum achievable B1 field strength that result in larger chemical shift displacements. 
Furthermore susceptibility differences between adjacent tissues have a greater effect on 
B0 homogeneity, which results in line broadening. Hence in this study we test the 
feasibility and reliability of 
31
P cardiac spectroscopy at 3 Tesla for clinical diagnostics 
using standard methods pre-implemented on a clinical MR scanner.  
 
Methods  
37 Controls (22 males) and 26 HCM patients (21 males) with symptomatic non-
obstructive cardiomyopathy, who provided written informed consent, were included in 
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the study.  The experiment was approved by the Regional Ethics Committee at 
Birmingham, UK.  All HVs were screened with history, echocardiography and 
metabolic exercise testing to rule out any structural heart diseases. All patients were 
recruited from cardiomyopathy clinics and had clinically proven diagnosis of non-
obstructive HCM.  
 
Patients selection 
Inclusion criteria: 
 Aged 18 to 80 years. 
 Fulfilled conventional echocardiographic criteria for the diagnosis of HCM 
(LV wall thickness greater than 1.5 cm in the absence of another cause for 
hypertrophy and without cavity dilatation) 
205, 206
.  
 Sinus rhythm. 
 Exertional symptoms. 
 Peak VO2 < 75% of predicted for age and gender. 
 
Exclusion criteria: 
   A resting or provocable LVOTO gradient > 30mmHg. Those patients were 
excluded because LVOTO is an important cause of symptoms and exercise 
limitation. 
. 
Controls selection 
Inclusion criteria: 
 Normal ECG.  
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 Normal Echocardiogram (LVEF ≥ 55%). 
 
Exclusion criteria: 
 History or symptoms of any medical illness. 
 
The subject characteristics are presented in Table 10.  The mean age of the HVs was 48 
± 16 years and that of HCM patients was 55 ± 13 (p = ns).   
 
 
 
Table 10: Baseline characteristics of HCM patients & controls - MRS 
reproducibility study. 
Parameter Controls 
(N=37) 
HCM 
(N=26) 
P Value 
Age (years) 48 ± 16 55 ± 13 ns 
Male sex –no (%) 22 (59) 21 (81) ns 
EF (%) 64 ± 6 64 ± 9 ns 
Peak VO2 (ml/kg/min) 39 ± 8 24 ± 6 <0.0001 
RER 1.2 ± 0.2 1.1 ± 0.1 ns 
Heart rate (bpm) 79.5 ± 11.7 67.5 ± 12.5 <0.01 
QTc interval (msec) 421.8 ± 16.0 455.9 ± 35.0 <0.01 
Systolic BP (mm Hg) 127.0 ± 20.4 126.1 ± 20.1 ns 
Diastolic BP (mm Hg)  79.5 ± 9.6 75.6 ± 10.7 ns 
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The mean EF on echocardiography was 64 ± 6% in controls and 64 ± 9% (p = ns) in 
HCM patients. None of the HVs had any structural heart disease or ECG abnormalities. 
31
P cardiac spectroscopy was performed eight times in one participant both on the same 
and on different days - to test the reproducibility and coefficient of variation of the test.  
 
31
P cardiac magnetic resonance spectroscopy was performed using a Phillips Achieva 
3T scanner and a linearly polarized transmit and receive 
31
P coil with a diameter of 14 
cm. Localization was achieved by ISIS 
160
 volume selection.  
 
The participants were positioned supine with the coil directly over the precordium. The 
3-D voxel of acquisition was planned to include most of the septum and apex of the 
heart. Care was taken to minimize blood contamination from the RV as much as 
possible. The voxel size was kept constant at 89.54ml (44 x 55 x 37 mm
3
) so that 
comparisons could be made between different subjects and scans. Following this the 
31
 
P spectra were acquired with a repetition time of 10000 ms, 136 averages and 512 
samples. A repetition time of 10000 ms was found to be optimal to adequately reduce 
saturation effects without increasing the scan time greatly. The spectral acquisition was 
ECG gated and the trigger delay was set to acquire spectra mainly in diastole. The 
trigger delay was measured by subtracting 250-300 msec from the total length of the 
cardiac cycle which allowed 250-300 msec of the cardiac cycle left for spectral 
acquisition (acquisition time is 170 msec). The total scan time was 23 minutes.  
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MRS Analysis 
The spectra were analysed and quantified on jMRUI software using AMARES a time 
domain fitting program 
161
. Cramer Rao lower bounds 
162
 and PCr/ATP ratio were 
calculated as previously described.  
 
Results 
A typical cardiac spectrum in HV as compared to HCM is shown in Figure 25.  
HCM Control
PCr
ATP2,3DPG
PDE
2,3DPG
PDE
PCr
ATP
 
 
 The PCR/ATP ratio was significantly lower in HCM (1.42 ± 0.51) as compared to 
healthy controls (2.11 ± 0.57, P < 0.0001) (Figure 26). The mean PCr/ATP ratio for the 
one participant with eight measurements was 2.11 ± 0.25 (Table 11).  Bland Altman 
plots were used as a test of reproducibility (Figure 27). The distribution of all the data 
Figure 25: Typical cardiac spectra in HCM and control.  
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points showed a good reproducibility with a variance of 12% in the measurement of 
PCr/ATP ratios which is within limits of agreement of repeated measurements.  
 
Figure 26: Box-plots of PCr/ATP ratios in controls and HCM patients.  
 
We also measured the line width of PCr peaks in the one participant who had 8 repeated 
scans. The mean line width was 1.36 ± 0.07 parts per million (ppm), Figure 28. The 
standard deviation of the line width was low which again confirmed the fact that the 
spectra were of good reproducible quality. 
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Table 11: Intra-subject MRS measurements.  
Table depicting the concentrations of 2, 3-DPG, ATP and PCr and the calculated PCr/ATP ratios 
from these measurements in the subject with eight measurements. (C): corrected for blood 
contamination. 
 
Subject No 
 
2,3 DPG 
sum 
 
PCr 
 
γ ATP 
 
γ ATP (C) 
 
PCr/γ 
ATP 
Ratio 
 
PCr/ γ 
ATP Ratio 
(C) 
Subject 1A 6.72E-04 4.90E-04 3.57E-04 2.45 E-04 1.37 2.00 
Subject 1B 4.27E-04 4.32E-04 3.21E-04 2.5 E-04 1.34 1.72 
Subject 1C 7.32E-04 6.53E-04 4.77E-04 3.55 E-04 1.36 1.83 
Subject 1D 1.00E-03 8.52E-04 5.12E-04 3.45 E-04 1.66 2.47 
Subject 1E 9.39E-04 5.53E-04 3.86E-04 2.3 E-04 1.43 2.40 
Subject 1F 8.29E-04 6.34E-04 4.26E-04 2.88 E-04 1.48 2.20 
Subject 1G 8.66E-04 5.36E-04 3.90E-04 2.46 E-04 1.37 2.18 
Subject 1H 8.32E-04 5.55E-04 4.05E-04 2.66 E-04 1.37 2.08 
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Figure 27: Bland-Altman plots of 
31
P cardiac Intra-subject MRS measurements.  
Graph plotted as difference in two measurements against mean of the same two measurements.  
 
As a further measure of the quality of spectra, we calculated the Cramer Rao lower 
bounds 162, which was 6 ± 1% for the PCr peak and 10 ± 1% for the gamma ATP peak. 
Cramer Rao lower bounds were calculated for the whole group, which was 12 ± 6% for 
the PCr peak and 17 ± 9% for the gamma ATP peak (Table 12). Due to an increase of 
susceptibility differences between heart muscle tissue, blood and air in the lungs at high 
field strength shim quality was slightly decreased at 3T in comparison to values 
reported for 1.5T cardiac spectroscopy. Hence multiplet splitting of the ATP resonances 
due to J-coupling is hardly visible. 
Bland Altman Plots for the test of reproducibility of Cardiac 
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Figure 28: Intra-subject line width of PCr peaks.  
Line width: 1.3625 ± 0.072 ppm.  
 
 
 
 
 
 
 
 
Table 12: Signal to Noise Ratio (SNR) assessment. 
Cramer Rao Lower bounds measured to test the quality of spectra.  
 
Groups 
 
PCr peak 
 
γ ATP Peak 
Healthy control (n = 1) 
(8 Measurements) 
6% ± 1 10% ± 1 
Whole group (n = 63) 
(Controls + HCM) 
12% ± 6 17% ± 9 
Controls (n = 37) 11% ± 5 16% ± 8 
HCM (n = 26) 12% ± 6 17% ± 9 
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Discussion 
Here we demonstrate that in-vivo cardiac 
31
P MRS at 3T is a reliable method of 
measuring high energy phosphate kinetics in the myocardium. We also show reduced 
PCr/ATP ratio in HCM patients known to have impaired cardiac energetics as measured 
in 1.5T systems 
32, 34
. The spectra show good reproducibility indicating that 
31
P cardiac 
MR spectroscopy is feasible on a clinical 3T MR system. The standard deviation for the 
PCr/ATP ratio for the whole group was low and comparable to previous published data 
on cardiac spectroscopy at 1.5 Tesla 
241
. This basic method of acquiring 
31
P spectra at 
3T using pre-implemented methods such as ISIS volume localisation and iterative 
shimming promises to be an important diagnostic and research tool. Possible 
applications are the comparison of PCr/ATP ratios in conditions like heart failure, 
ischaemic heart disease and valvular heart disease. It might also be used to monitor 
disease progression and study effects of medications like metabolic modulators in heart 
disease.  
 
Cardiac spectroscopy at 3T continues to face some challenges which are present at 1.5T 
as well, but some of them are even more pronounced at high field strength. One main 
drawback of cardiac spectroscopy is the effect of respiratory motion and movement of 
the heart itself. This can result in contamination from liver and skeletal muscle of the 
chest wall. Careful localization of the voxel ensures minimal contamination. We 
particularly paid attention to this aspect while planning our voxel of acquisition. 
Provided the voxel is positioned carefully, no significant advantages to the quality of 
spectra acquired with multiple outer volume suppression bands was observed.  None of 
our spectra show any significant contamination with skeletal muscle or liver. It is also 
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important to ensure that the spectral acquisition is done when the heart motion is at its 
minimum. This is during diastole and we set the trigger delay such that all of the 
spectral acquisition happened during diastole. One other problem is the respiratory 
motion. This could be partially negated by acquiring the spectra with respiratory gating 
as well as cardiac gating (double triggered) and volume tracking 
242, 243
. Further 
developments in these techniques should improve quality of cardiac spectra and reduce 
the contamination from surrounding structures. 
 
Higher field strength of 3T offers better spatial resolution and SNR. These effects have 
been particularly noted in proton spectroscopy of the human brain 
244
. However, 
increasing susceptibility differences between muscle tissue, blood and air in the lungs 
cause increased B0 field inhomogeneities and hence problems with shim convergence. 
Various shimming techniques like iterative and FASTMAP based 
245
 higher order 
shimming were compared. Localized iterative 1st order shimming based on a volume 
including the entire heart offered the best and most reproducible shim quality. However, 
there is definitely scope for further improvement in shimming techniques. One 
possibility might be localized shimming based on cardiac triggered B0-mapping as 
reported earlier for cardiac imaging at 3T 
246
. Another problem is the shortened 
transverse relaxation times (T2) at 3T in comparison to 1.5T. This causes an additional 
increase in line width of the various peaks. 
 
No significant advantages to the quality of spectral acquisition using proton decoupling 
or Nuclear Overhauser Enhancement (NOE) were found. Therefore these techniques 
were not used. Although NOE can increase the SNR by up to 40%, this is not useful for 
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experiments where quantification is required. NOE in particular imparts different 
amount of energy to phosphates in ATP and PCr which can result in altered PCr/ATP 
ratio. This is particularly important as the effect of NOE is different for distinct 
molecules and depends on conditions as the pH which might be changed in the diseased 
myocardium.  
 
Due to a decrease of the maximum achievable B1 field strength at 3T together with an 
increase in spectral separation compared to 1.5T, the bandwidth of the excitation pulse 
was limited and hardly sufficient to excite the entire frequency range of interest. Using a 
simple surface coil this is especially a problem in large penetration depth. In addition, 
the excitation profile was not homogeneous. Hence different flip angles were applied to 
spins with different offset frequencies. This resulted in a frequency dependent weighting 
of peak intensities. Hence, the intensity of the beta ATP peak, which has a large 
frequency offset compared to PCr, was always significantly decreased or even lost in 
obese subjects, where the distance between coil and VOI is large. However the 
determined PCr/gamma-ATP ratios were not affected, because the frequency difference 
between both resonances is small and the pulse frequency offset was chosen to be in-
between of both.  
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CHAPTER 7: MYOCARDIAL ENERGY DEFICIENCY IN 
HCM: RELATION TO EXERCISE CAPACITY AND 
DYNAMIC SYSTOLIC AND DIASTOLIC DYSFUNCTION 
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Abstract 
 
Introduction: Previous studies had shown that hypertrophic cardiomyopathy (HCM) 
patients manifest impaired cardiac energetics. We hypothesized that reduced cardiac 
energetic status would result in dynamic impairment of both diastolic and systolic 
function upon exercise and contribute to exercise limitation.    
 
Methods: 51 symptomatic non-obstructive HCM patients (39 male and mean age of 54 
years) and 33 age and gender matched controls were enrolled.   All participants had an 
ECG, echocardiogram and cardiopulmonary exercise test.  We measured radionuclide 
indices of left ventricular diastolic filling (Time To Peak Filling [TTPF]) and 
normalised this for heart rate (nTTPF), LV end systolic elastance index (ELVI) and 
vasculoventricular coupling (VVC) ratio at rest and during submaximal exercise (50% 
of heart rate reserve). Myocardial energetic status (PCr/γ ATP ratio) was measured by 
31
P magnetic resonance spectroscopy (MRS). 
 
Results: HCM patients exhibited marked exercise limitation vs healthy controls (peak 
VO2 24 ± 6 vs  38 ± 8 ml.kg-1.min-1, p < 0.0001), and reduced PCr/γATP ratio (1.41 ± 
0.48 vs 2.26 ± 0.59 , p < 0.0001). nTTPF (normalised for heart rate) fell during 
submaximal  exercise in controls (0.19 ± 0.09 to 0.16 ± 0.08 sec), but increased 
significantly in patients (0.17 ± 0.07 to 0.32 ± 0.09 sec) , (p < 0.0001).  The increase in 
ELVI was greater in controls (relative increase 1.7±0.7 vs 1.24±0.68, p<0.05). The VVC 
ratio decreased on exercise in controls but was unchanged in HCM patients (0.60 ± 0.21 
vs 0.41 ± 0.15, p = 0.003 and 0.55 ± 0.35 vs 0.46 ± 0.24, p = 0.28, respectively). PCr/ γ 
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ATP ratio correlated significantly with nTTPF during exercise (r = - 0.47, p = 0.003), 
with peak VO2 (r = 0.52, p < 0.001) and with δVVC ratio (r = - 0.4, p = 0.02). 
 
Conclusion: HCM patients have impaired myocardial energetics which correlates 
significantly with exercise capacity, and is associated with dynamic diastolic and 
systolic dysfunction. This study provides a rationale for further consideration of 
metabolic therapies in HCM.  
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Introduction 
Biochemical and biophysical analyses of the mutant sarcomeric proteins that cause 
HCM led Watkins and colleagues to propose that energy depletion may underlie HCM 
91-93
. Consistent with this, unexplained left ventricular hypertrophy is a feature of 
disorders associated with mutations in a variety of metabolic genes that lead to defects 
in energy production in the heart 
91
. In a recent study using in vivo cardiac MR 
spectroscopy, resting PCr/γATP ratio was diminished in patients with sarcomeric HCM, 
indicating reduced energy availability 
34
.  Importantly, patients with genotypic HCM 
who did not yet have hypertrophy had a similar degree of impairment of cardiac 
PCr/γATP ratio as seen in patients with marked hypertrophy, implying that the 
disturbance may be an early feature of the disease and is not simply due to the 
hypertrophy 
32
.  
 
Diastolic dysfunction contributes significantly to the genesis of breathlessness in HCM 
patients. Active relaxation is typically slowed and filling rate diminished at rest in these 
patients 
14
. Furthermore, our group previously showed that, on exercise there is 
frequently a failure of the normal increase in the rate of active relaxation on exercise, 
indeed in some patient‘s active relaxation paradoxically slowed on exertion 15.  Whilst 
resting measures of diastolic function were rather poorly related to exercise capacity, 
TTPF (an indirect measure of the rate of LV active relaxation) assessed during 
submaximal exercise was strongly related to peak oxygen consumption 
15
. Izawa and 
colleagues subsequently confirmed these non invasive observation using invasive 
measures of active relaxation 
16
.  
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In this study, we assessed the relationship between exercise capacity, cardiac energetic 
and diastolic and systolic function at rest and during exercise in HCM patients and 
controls. We used in vivo cardiac 
31P MR spectroscopy to measure resting PCr/γATP 
ratio as a marker of cardiac energetic status and we used rest and exercise radionuclide 
ventriculography to measure diastolic filling of the left ventricle, LV end systolic 
elastance index (ELVI) and vasculoventricular coupling (VVC) at rest and during 
exercise. 
 
Methods 
51 HCM patients (39 males) and 33 controls (20 males), who provided written informed 
consent, were included in the study.  Characteristics and treatment of participants are 
shown in Table 13.  The study was approved by the South Birmingham Research Ethics 
Committee and the investigation conforms to the principles outlined in the Declaration 
of Helsinki.  All study participants had ECG, echocardiogram and metabolic exercise 
test. 5 healthy controls were excluded from MRS studies due to claustrophobia.  15 
HCM patients were excluded from MRS studies – 8 due to claustrophobia, 4 had poor 
quality spectra either due to inadequate ECG gating or shimming, and 3 were deemed 
unsafe to have MRS studies due to potential risk of metal bodies in eyes. 
 
Patient selection 
Patients were consecutively recruited from cardiomyopathy clinics at the Heart 
Hospital, University College London Hospitals, London and Queen Elizabeth Hospital, 
Birmingham, UK between 2006 and 2008.  
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Inclusion criteria:  
 Age 18 to 80 years. 
 Exertional symptoms. 
 Sinus rhythm.  
 Peak VO2 < 75% of predicted for age and gender. 
 
Exclusion criteria:  
 Presence of resting or provocable LVOT obstruction (peak gradient > 30 mm Hg).  
 Presence of epicardial coronary artery disease.  
 Diabetic patients.  
 
Controls selection 
Inclusion criteria: 
 Normal ECG.  
 Normal Echocardiogram (LVEF ≥ 55%). 
 
Exclusion criteria: 
 History or symptoms of any medical illness. 
 
Cardiopulmonary Exercise Test 
All study participants underwent symptom-limited erect treadmill exercise testing 
(Schiller CS-200 Ergo-Spiro exercise machine) using a standard ramp protocol with 
simultaneous respiratory gas analysis 
158
. Peak oxygen consumption (peak VO2) was 
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defined as the highest peak VO2 achieved during exercise (with RER >1) expressed in 
ml/min/kg.  
 
Transthoracic Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position 
with a Vivid 7 echocardiographic machine (GE Healthcare) and a 2.5-MHz transducer. 
LVEF was derived from a modified Simpson‘s formula. LA volume index and MWT 
were measured. Pulse and continuous wave Doppler were used to assess resting 
LVOTO gradient. 
 
Radionuclide Ventriculography  
Diastolic filling was assessed by equilibrium R-wave gated blood pool scintigraphy at 
rest and during graded semi-erect exercise on a cycle ergometer as previously described 
221, 247
.  Peak left ventricular filling (end-diastolic count per second (EDC/s)) and time to 
peak filling normalised for R-R interval (nTTPF), an indirect measure of the rate of LV 
active relaxation  were assessed  at rest and during exercise (50% of heart rate reserve). 
The validity of these radionuclide measures of diastolic filling at high heart rates has 
been established previously 
221, 247
. The following indexes were calculated: arterial 
elastance index (EaI) and LV end-systolic elastance index (ELVI) as previously 
described by our group 
248
 and others 
249
. VVC is an index of the interaction between 
arterial and ventricular elastic properties, which is an important determinant of cardiac 
performance. It is defined by the ratio of arterial elastance (EaI) to left ventricular 
systolic elastance (ELVI) 
249
. δVVC Ratio was defined as the net difference between 
exercise and resting VVC ratio.  
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31
P Cardiac Magnetic Resonance Spectroscopy (MRS) 
In vivo myocardial energetics were measured using a MRS at 3-Tesla Phillips Achieva 
3T scanner, as previously validated 
250
. A Java magnetic resonance user interface v3.0 
(jMRUI) was used for analysis 
251
. PCr and γ-ATP peaks were used to determine the 
PCr/ATP ratio which is a measure of the cardiac energetic state. Data were analyzed by 
an investigator who was blinded to the participants‘ clinical status. Cramér–Rao ratios 
were used to assess signal: noise ratio 
250
. Example of HCM 
31
P cardiac spectra is 
shown in Figure 29.  
 
 
 
 
 
 
 
 
 
 
Figure 29: An example of 
31
P cardiac spectra of a HCM patient. 
C indicates centre of phosphorus coil, VOI; voxel of interest, 2, 3-DPG indicates 2, 3-
diphosphoglycerate; PDE, phosphodiesters; PCr, phosphocreatine; α, β, γ indicate the three 
phosphorus nuclei of ATP. 
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Statistics 
Data were analyzed using SPSS ver. 15.0 for Window and Microsoft Office Excel 2007, 
and expressed as mean ± standard deviation (SD).  Comparisons of variables were 
determined by Student‘s t-test (2-tail) if variables were normally distributed and the 
Mann-Whitney U-test if the data were non-normally distributed.  Categorical variables 
were compared with the Pearson chi-square test. A difference of p < 0.05 was taken to 
indicate statistical significance. Pearson‘s correlation coefficient was used to describe 
the relationship between variables.  Another analysis was performed after excluding 
HCM patients who were on beta blockers therapy. 
 
Results 
The clinical characteristics and cardiopulmonary exercise test results of HCM patients 
and controls are shown in Table 13.  Both groups were well matched with respect to age 
and gender.  HCM patients exhibited marked exercise limitation as compared to 
controls whereas mean EF was comparable in both groups.  Heart rate was lower in the 
HCM group, as compared to controls, probably due to rate limiting medication (beta 
blockers or/and calcium channel blockers).    
 
Conventional Echocardiographic Measurements 
Standard, Doppler and PW-TDI echocardiographic findings of HCM and controls 
groups are listed in Table 14.  Transmitral Doppler measurements showed no significant 
difference in peak E and A, and E/A ratio in HCM versus controls (Table 14).  
However, PW-TDI measurements of Sm, Em and Am of the inferoseptal and 
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anterolateral basal segments were significantly lower in HCM patients compared to 
controls (Table 14).   
Parameter  HCM  Controls  P value  
 
Age [years] 
 
54 ± 12 
 
52 ± 15 
 
0.4 
Number (Male)  51 (35)  33 (20)  0.64 
Heart Rate [bpm] 69 ± 14 82 ± 16  < 0.001* 
Systolic BP [mm Hg] 126 ± 21 126± 21 0.91 
Diastolic BP [mm Hg] 75 ± 12 78 ± 11 0.3 
Peak Vo2 [ml/kg/min]  24 ± 6  38 ± 8  < 0.0001* 
% Predicted peak Vo2 [%] 66 ± 14  101 ± 18 < 0.0001* 
Drug therapy – no. (%)    
     Diuretic 10 (20) 0 - 
     ACE inhibitor 6 (12) 0 - 
     ARB 1 (2) 0 - 
     Beta-blocker 20 (39) 0 - 
     Calcium channel blocker 26 (51) 0 - 
     Aspirin 13 (25) 0 - 
     Warfarin 5 (10) 0 - 
     Nitrate 2 (4) 0 - 
     Statin 15 (29) 0 - 
Table 13: The clinical characteristics of HCM patients and controls – Correlation 
study.  
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Parameter  
 
HCM  
 
Controls  
 
P value  
 
EF Biplane (%)  
 
65 ± 9  
 
63  ± 6  
 
0.2 
Biplane LA Volume (ml) 78 ± 30 39 ± 20 < 0.0001* 
LA Volume Index (ml/m
2
) 37 ± 17 15 ± 13 < 0.0001* 
MV E (m/s) 0.70 ± 0.17 0.66 ± 0.15 0.34 
MV A (m/s) 0.67 ± 0.24 0.59 ± 0.14 0.06 
MV E/A ratio 1.16 ± 0.5 1.17 ± 0.38  0.89 
MV Dec Time (ms) 239 ± 76  260  ± 70  0.27 
Antlat Sm (cm/s) 0.06 ± 0.02  0.09 ± 0.02 < 0.0001* 
Antlat Em (cm/s) 0.08 ± 0.03   0.10 ± 0.04 < 0.0001* 
Antlat Am (cm/s) 0.06 ± 0.03    0.10 ± 0.03 < 0.0001* 
Infsep Sm (cm/s) 0.06 ± 0.02    0.08 ± 0.02 0.0001* 
Infsep Em (cm/s) 0.05 ± 0.02   0.07± 0.03   < 0.0001* 
Infsep Am (cm/s) 0.07 ± 0.02   0.09 ± 0.02  0.0001* 
Average Sm (cm/s) 
Average Em (cm/s) 
0.06 ± 0.02    
0.06 ± 0.02   
0.08 ± 0.02 
0.09 ± 0.04 
< 0.0001* 
< 0.001* 
E/Em antlat 9.84 ± 4.09   6.94 ± 2.28 0.001* 
E/Em infsep 17.28 ± 7.32    9.55 ± 3.79   < 0.0001* 
E/Em average 11.93 ±  4.39 8.03 ± 3.28   < 0.0001* 
 
Table 14: Standard, Doppler and PW-TDI Echocardiographic characteristics of 
HCM vs controls - Correlation study.  
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In vivo Cardiac Energetics 
At rest, cardiac PCr/γATP ratio in all HCM patients and excluding those on beta 
blockers were significantly reduced compared to controls (1.41 ± 0.48 vs 2.26 ± 0.59, p 
< 0.0001 and  1.35 ± 0.48 vs 2.26 ± 0.59, p < 0.0001 respectively) (Figure 30). 
 
 
 
Figure 30: Cardiac PCr/γATP ratio in HCM patients and controls.  
A represents all HCM patients and all controls whereas B represents HCM patients not on beta 
blockers and all controls.  Both HCM groups exhibit significant reduction in cardiac energetics 
compared to controls. 
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Radionulcide Diastolic Indices 
 At rest, nTTPF was similar in HCM patients and controls (0.17 ± 0.07 sec vs 0.19 ± 
0.09 sec) (p = 0.38). During submaximal exercise (at a workload that achieved 50% of 
heart rate reserve) it shortened in controls (from 0.19 ± 0.09 sec to 0.16 ± 0.08 sec), but 
lengthened in patients (from 0.17 ± 0.07 sec to 0.32 ± 0.09 sec) p < 0.0001 and  this was 
similar after excluding HCM patients on beta blockers (Figure 31).  
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Figure 31: nTTPF at rest and during exercise (50% workloads of heart rate 
reserve).  
A-represents comparison in nTTPF between all HCM patients and controls whereas B- represents 
comparison, between HCM* patients (excluding patients taking beta blockers) and controls. 
During exercise, nTTPF had shortened in controls but lengthened in HCM patients. There were 
similar results in both groups. 
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Vasculo-Ventricular Coupling 
Consistent with a previous study 249, VVC ratio decreased significantly on exercise in 
healthy control subjects (0.60 ± 0.21 vs 0.41 ± 0.15, p = 0.003). However, there was a 
blunt response in HCM patients as with VVC essentially unchanged during exercise 
(0.55 ± 0.35 vs 0.46 ± 0.24, p = 0.28.) δVCC Ratio decreased significantly in the 
controls group as compared to the HCM group (Figure 32).  
 
 
Figure 32: δVCC Ratio in HCM patients and controls.  
A-represents comparison in δVCC between all HCM patients and controls whereas B- represents 
comparison, between HCM* patients (excluding patients taking beta blockers) and controls. There 
was a significant change in the control group whereas the HCM group showed a blunt response in 
VVC ratio. These results remained unchanged statistically even after excluding HCM patients on 
B-Blockers (panel B).  
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The difference in VVC responses was principally due to a significantly greater increase 
in LV contractility (relative Δ ELVI) in controls during exercise compared to HCM 
patients (Figure 33). There was no significant difference in the change in arterial 
elastance during exercise (relative Δ Eal) between the two groups (Figure 34). These 
results remained unchanged statistically even after excluding HCM patients on B-
Blockers. 
 
 
 
Figure 33: Relative Δ (ELVI) in HCM patients and controls.  
A-represents comparison in relative Δ (ELVI) between all HCM patients and controls whereas B- 
represents comparison, between HCM patients (excluding patients taking beta blockers) and 
controls. Relative Δ ELVI = ELVI exercise / ELVI rest. There was a significant increase in the control 
group whereas the HCM group showed a blunt response in relative Δ (ELVI). These results 
remained unchanged statistically even after excluding HCM patients on B-Blockers (panel B).  
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Figure 34: Relative Δ (EaI) in HCM patients and controls.  
A-represents comparison in relative Δ (EaI) between all HCM patients and controls whereas B- 
represents comparison, between HCM patients (excluding patients taking beta blockers) and 
controls. Relative Δ EaI = EaI exercise / EaI rest. There was no significant difference in the change 
in arterial elastance during exercise (relative Δ Eal) between the two groups. These results 
remained unchanged statistically even after excluding HCM patients on B-Blockers (panel B).  
 
 
Relationship to in vivo cardiac energetics 
PCr/γATP ratio correlated inversely with nTTPF during exercise (r = - 0.48, p = 0.003) 
and with VVC ratio (r = - 0.4, p = 0.02), but positively with peak VO2 (r = 0.52, p < 
0.001), (Figure 35). These correlations remained significant even after excluding 
patients on beta blockers (Figure 36). 
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Figure 35: Relationship to in vivo cardiac energetics.  
Panel A: Cardiac PCr/γATP ratio correlated positively with exercise capacity (peak VO2).  Panel B: 
Cardiac PCr/γATP ratio correlated negatively with nTTPF (exercise). Panel C: Cardiac PCr/γATP 
ratio correlated negatively with δ VVC ratio.  
 
Discussion 
The purpose of this study was to test the hypothesis that impaired cardiac eneregtic 
status is associated with the previously described dynamic disturbance of LV active 
relaxation occurring on exercise in patients with HCM, and also to assess whether there 
is also a dynamic impairment of contractile function on exercise. The principal findings 
are: a) Consistent with previous studies, HCM patients demonstrate reduced resting 
myocardial energetic status 
32, 34, 252
 and a paradoxical slowing of LV relaxation on 
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exercise 
15
. b) Whereas in healthy controls LV contractile status increased upon exercise 
resulting in a marked reduction in the vasculo-ventricular coupling ratio, LV contractile 
status was not augmented in HCM and vasculo-ventricular coupling ratio was 
unchanged c) Cardiac energetic status correlated positively with exercise capacity and 
d) was inversely correlated with nTTPF during submaximal exercise (a measure of the 
rate of LV active relaxation) and with δVVC ratio.  
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Figure 36: Relationship to in vivo cardiac energetics (excluding HCM patients on 
beta blockers).  
Panel A: Cardiac PCr/γATP ratio correlated positively with exercise capacity (peak VO2).  Panel B: 
Cardiac PCr/γATP ratio correlated negatively with nTTPF (exercise). Panel C: Cardiac PCr/γATP 
ratio correlated negatively with δ VVC ratio. These correlations remained significant after 
excluding patients on beta blockers and were similar to the results in the whole HCM group shown 
in Figure 35. 
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The pathophysiology of HCM is complex. A substantial proportion of these patients 
complain of breathlessness and/or fatigue and most have reduced exercise capacity 
15
.  
These patients typically exhibit impaired LV active relaxation at rest and/or during 
exercise. This has led many to conclude that exercise limitation is primarily a result of 
impaired LV diastolic filling. Somewhat surprisingly our data show no significant 
difference in nTTPR at rest between HCM and controls.  This could be at least in part 
because the mean age of our population of patients (and in consequence controls) is 
rather older than previous studied populations 
15, 253, 254
. Nevertheless, on exercise 
patients and controls behaved very differently, with nTTPF shortening in healthy 
controls during submaximal exercise but lengthening in patients, consistent with our 
previous study 
15
.  The change in nTTPF on exercise was inversely related to the resting 
cardiac PCr/ATP ratio. This parameter is a measure of cardiac energy ‗reserves‘. In both 
HCM and heart failure PCr is depleted to a greater extent than ATP resulting in a fall in 
the ratio of PCr/ATP 
34, 86
. PCr represents a rapid source of ATP under conditions of 
stress such as exercise. The rate at which ATP can be regenerated from PCr is 
approximately 10 fold faster than the rate of De Novo synthesis of ATP. The presence of 
a reduced resting PCr/ATP ratio therefore indicates a reduction in energy ‗reserves‘ 
likely to be exacerbated during exercise. Because of the duration of acquisition required 
to obtain MRS spectra it was not however possible to measure PCr/ATP ratio on 
exercise. 
 
Patients with flow limiting coronary disease and diabetes were excluded to avoid the 
confounding influence of impaired cardiac energetic status associated with these 
disorders 
255, 256
. MRS and Radionuclide studies also require a regular rhythm, thus 
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patients with atrial fibrillation were excluded from the study. In addition, we excluded 
patients with significant LVOT obstruction (gradients > 30 mmHg) which will 
significantly disrupt the acquisition of radionuclide indices of diastolic filling.  A 
proportion of patients were on β-blockers which may have affected their cardiovascular 
response to exercise, however, all heart rate dependent parameters were corrected. 
Furthermore, the level of significance remained similar when these patients on β-
blockers were excluded from the analysis.    
 
In summary, in the present study, exercise led to paradoxical slowing of the rate of 
active relaxation of the LV compared to a shortening in controls. Furthermore, there 
was a failure of the normal increase in contractility during exercise.  Resting cardiac 
energetic status was substantially reduced in HCM patients, which is supported by other 
studies 
32, 34
. We propose that energetic impairment may underlie these dynamic 
changes in active relaxation and contractility and contribute significantly to exercise 
limitation. These findings may indicate the potential for therapeutic benefit from 
‗metabolic agents‘ that improve myocardial energetic status by altering cardiac substrate 
use 
257
. These agents have shown promise in ischaemic heart disease 
67, 114, 258-260
and in 
heart failure 
261, 262
. 
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CHAPTER 8:  METABOLIC MODULATION WITH 
PERHEXILINE CORRECTS ENERGY DEFICIENCY AND 
IMPROVES EXERCISE CAPACITY IN SYMPTOMATIC 
HCM 
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Abstract 
Background Patients with HCM exhibit myocardial energetic impairment, but a 
causative role for this energy deficiency in the pathogenesis of HCM remains unproven. 
We hypothesized that the metabolic modulator, perhexiline would ameliorate 
myocardial energy deficiency and thereby improve diastolic function and exercise 
capacity.   
 
Methods Forty six consecutive patients with symptomatic exercise limitation (peak 
oxygen consumption - peak VO2 <75% of predicted) due to non-obstructive HCM (mean 
age 55 ± 0.26 years old) were randomized to perhexiline (n=24) or placebo (n=22). 
Myocardial energetics (PCr/ATP ratio) measured by 31P magnetic resonance 
spectroscopy, left ventricular diastolic filling [heart rate normalized time to peak filling 
nTTPF] at rest and during exercise using radionuclide ventriculography, peak VO2, 
symptoms and QOL were assessed at baseline and at the end of the study (4.6 ± 1.8 
months).  
 
Results Perhexiline improved the PCr/ATP ratio (from 1.27 ± 0.02 to 1.73 ± 0.02; p = 
0.003) and normalised the abnormal prolongation of nTTPF between rest and exercise 
(nTTPF – 0.01 ± 0.005 vs + 0.11 ± 0.008 sec; p = 0.03). These changes were 
accompanied by improvement in peak VO2 (22.2 ± 0.2 to 24.29 ± 0.2 ml/kg/min; p = 
0.003) and symptoms (NYHA class by 0.8 units p <0.001) (all p values ANCOVA). 
 
Conclusions Modulation of myocardial metabolism with perhexiline in patients with 
HCM ameliorates cardiac energetic impairment, corrects diastolic dysfunction and 
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increases exercise capacity. This study supports the hypothesis that energy deficiency 
contributes to the pathogenesis and provides a rationale for further consideration of 
metabolic therapies in HCM. 
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Introduction 
HCM is the commonest inherited cardiac condition (prevalence ~0.2%).
4
 Symptoms 
arising from left ventricular outflow tract obstruction (LVOTO), are present in ~30% of 
HCM patients, are amenable to drug therapies and to interventions such as surgical 
septal myectomy or alcohol septal ablation 
263
. However, treatment options in 
symptomatic patients without obstruction are less successful, mandating a better 
understanding of the mechanisms underlying symptoms in HCM with the intention of 
identifying and testing novel therapies 
264, 265
. 
 
HCM is a disease of the sarcomere, with >400 mutations having been identified in 
genes encoding cardiac contractile proteins 
2
. HCM-causing mutations increase 
sarcomeric Ca2+ sensitivity, ATPase activity and the energetic cost of myocyte 
contraction 
266-269
. These abnormalities led to the proposal that the pathophysiology of 
HCM is attributable, at least in part, to excessive sarcomeric energy use 
270
. The 
resulting hypertrophy of HCM, accompanied by significant microvascular dysfunction, 
271
 may limit myocyte oxygen delivery and further exacerbate the primary energy 
deficiency 
235
. Consistent with a functional role for the observed energy deficiency of 
HCM 
32, 34
, LV relaxation (a highly energy requiring process), paradoxically slows on 
exercise and is correlated with exercise limitation 
15
. To assess a causative role for 
energy deficiency and to test a potentially novel therapeutic strategy for HCM, we 
evaluated whether perhexiline, an agent thought to improve cardiac energetics by 
shifting myocardial substrate utilization to more efficient carbohydrate metabolism 
66, 99, 
272, 273
,  would increase exercise capacity by improving cardiac energetics and diastolic 
filling.  
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Methods 
Study Design 
The study was approved by the South Birmingham Research Ethics Committee and 
conforms to the principles outlined in the Declaration of Helsinki. All participants 
provided written informed consent. The study was a randomized, double blind, placebo-
controlled parallel-group design of minimum 3 months duration (Figure 37). The pre-
defined primary end point was peak oxygen consumption (peak VO2) and secondary end 
points were symptomatic status, resting myocardial energetics (PCr/ATP ratio) and 
diastolic function at rest and during exercise (nTTPF). Thirty three controls of similar 
age and gender distribution were recruited for comparison of baseline data. Controls 
were asymptomatic and had normal ECGs and echocardiograms. 
 
Patient selection 
Patients were consecutively recruited from cardiomyopathy clinics at the Heart 
Hospital, University College London Hospitals, London and Queen Elizabeth Hospital, 
Birmingham, UK between 2006 and 2008.  
 
Inclusion criteria:  
 Age 18 to 80 years.  
 Exertional symptoms. 
 Sinus rhythm.  
 Peak VO2 < 75% of predicted for age and gender. 
 Absence of LVOT obstruction at rest (peak gradient < 30mmHg).  
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Figure 37: Perhexiline Trial profile. 
HCM patients assessed for 
eligibility into the study 
N= 1300 
 
Deemed eligible for the study 
N= 330  
 
 Consecutive consenting patients 
recruited into the study 
N= 46  
 
 Baseline studies 
 
 
Randomization 
 
 
Allocated to Perhexiline (n=24) 
  
   
 
 
Allocated to Placebo (n=22) 
   
 
 
Baseline and follow up 
studies; 
 
Symptomatic status 
Cardiopulmonary exercise test  
31 P MRS  
Radionuclide ventriculography   
Perhexiline plasma assay  
at 7days and 4 week  
 
 
Follow up studies 
 
 End of studies 
 
15 patients (n= 6 on placebo 
and n= 9 on perhexiline) were 
excluded from MRS studies 
due to:   
 
- Contraindication to MRI      
   (11 patients had ICD)  
-  Claustrophobia (4 patients) 
Follow up 
duration 
4.6 ± 1.8 
Months 
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Exclusion criteria:  
 Presence of epicardial coronary artery disease. 
 Abnormal liver function tests. 
 Concomitant use of amiodarone or selective serotonin reuptake inhibitors (due to 
      potential drug interactions with perhexiline).  
 Peripheral neuropathy.  
 Women of childbearing potential.  
 Diabetic patients were also excluded to maintain the blinding of the study as  
     perhexiline may lead to a reduction in plasma glucose necessitating a reduction in    
     anti-diabetic therapy.  
 
Controls selection 
Inclusion criteria: 
 Normal ECG.  
 Normal Echocardiogram (LVEF ≥ 55%). 
 
Exclusion criteria: 
 History or symptoms of any medical illness. 
 
Cardiopulmonary Exercise Test 
All study participants underwent symptom-limited erect treadmill exercise testing 
(Schiller CS-200 Ergo-Spiro exercise machine) using a standard ramp protocol with 
simultaneous respiratory gas analysis 
158, 159
. Peak oxygen consumption (peak VO2) was 
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defined as the highest peak VO2 achieved during exercise (with RER >1) expressed in 
ml/min/kg.  
 
Symptomatic status assessment 
Symptom status was determined by a single investigator (KA) using the NYHA 
functional classification. All patients completed a MLHF questionnaire at baseline and 
at the end of the treatment phase.  
 
Transthoracic Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position 
with a Vivid 7 echocardiographic machine (GE Healthcare) and a 2.5-MHz transducer. 
LVEF was derived from a modified Simpson‘s formula. LA volume index and MWT 
were measured. Pulse and continuous wave Doppler were used to assess resting 
LVOTO gradient. 
 
Radionuclide Ventriculography  
Diastolic filling was assessed by equilibrium R-wave gated blood pool scintigraphy at 
rest and during graded semi-erect exercise on a cycle ergometer as previously described 
221, 247
.  Peak left ventricular filling (end-diastolic count per second (EDC/s)) and time to 
peak filling normalised for R-R interval (nTTPF), an indirect measure of the rate of LV 
active relaxation were assessed  at rest and during exercise (50% of heart rate reserve). 
The validity of these radionuclide measures of diastolic filling at high heart rates has 
been established previously 
221, 247. 
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31
P Cardiac Magnetic Resonance Spectroscopy (MRS) 
In vivo myocardial energetics were measured using a MRS at 3-Tesla Phillips Achieva 
3T scanner, as previously validated 
250
. A Java magnetic resonance user interface v3.0 
(jMRUI) was used for analysis 
251
. PCr and γ-ATP peaks were used to determine the 
PCr/ATP ratio which is a measure of the cardiac energetic state. Data were analyzed by 
an investigator who was blinded to the participants‘ clinical status. Cramér–Rao ratios 
were used to assess signal: noise ratio 
250
.  
 
Intervention 
Following baseline studies, patients were randomized in a double-blind fashion to 
receive either perhexiline 100 mg OD (n = 24) or placebo (n = 22). Serum perhexiline 
levels were obtained at 1 and 4 weeks after initiation of the drug. Dose adjustments 
were advised by an unblinded physician according to serum level to achieve therapeutic 
level (therapeutic range 0.15-0.6 mg/l) and to avoid drug toxicity (Table 15 & Table 
16). Identical dosage adjustments were also made for randomly allocated placebo-
treated patients by the unblinded observer to ensure that blinding of the investigators 
was maintained. 
 
Statistical Analysis 
Data were analyzed using SPSS version 15.0 for Window and Microsoft Office Excel 
2007, and expressed as Mean ± Standard Error of Mean (SEM). Comparison of 
continuous variables between perhexiline and placebo baseline data were determined by 
unpaired Student‘s t-test (2-tail) if variables were normally distributed and the Mann-
Whitney U-test if the data were non-normally distributed. 
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Perhexiline concentration (mg/L) Recommended new daily dose (mgs) 
 
0.00-0.05 
300 
0.05-0.15 250 
0.15-1.00 200 
1.00-1.50 100 
1.50-2.00 50 
>2.00 
 
Cease for 1 week then 50 mg on alternative 
 days 
Table 15: Dose planning based on perhexiline assays result on day 7 
Perhexiline concentration( mg/L) Recommended new daily dose (mgs) 
<0.15 Double the daily dose 
0.15-0.60 No change 
0.60-0.90 Reduced dose by 25% 
0.90-1.20 Halve the daily dose 
>1.20 
 
Cease for 1 week then reduce the daily dose  
25% of the previous dose 
Table 16: Dose planning based on perhexiline assays result at ≥ 4 weeks. 
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ANCOVA with baseline values as covariates was performed to test for the significance 
of differences in the perhexiline versus placebo group after treatment. A p value of 0.05 
was taken to indicate statistical significance. For the primary end point, forty four 
patients are required to detect a change in peak VO2 of 3 ml/kg/min in the treatment 
versus the placebo group with a power of 90% and a p value of <0.05. Thirty patients 
are required to identify a 5 % change in cardiac PCr/ATP ratio with a power of 90% 
and a p value of <0.05. Forty patients are required to detect a change ≥25 % in nTTPF 
with power of 0.99 with probability of 5%.  
 
Results 
Baseline data (HCM versus Controls) 
The clinical characteristics and cardiopulmonary exercise test results of the HCM 
patients and controls are shown in Table 17. The groups were well matched with respect 
to age and gender. Heart rate was lower in the HCM group compared to controls 
probably due to medications used (beta blockers and/or calcium channel blockers).  
 
Resting cardiac PCr/ATP ratio was lower in HCM patients than in controls (1.28 ± 
0.01 vs 2.26 ± 0.02, p < 0.0001) (Figure 38), and this remained so after excluding 
patients taking beta blocker therapy (p < 0.0001). At rest, nTTPF, a sensitive marker of 
LV relaxation, was similar in HCM patients and controls (0.17 ± 0.002 vs 0.18 ± 0.003 
sec, p = 0.44).  
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Table 17: The clinical characteristics of HCM patients and controls – Perhexiline 
trial.  
 
Parameter 
 
HCM  
 
Controls 
 
P value 
 
HCM 
(Perhexiline) 
 
HCM 
(Placebo) 
 
P value  
 
Age [years] 
 
55 ± 0.26 
 
52 ± 0.46 
 
0.2 
 
56 ± 0.46 
 
54 ± 0.64 
 
0.42 
Number (Male)  46 (34) 33 (20) 0.64 24 (19) 22 (17) 0.69 
Heart Rate [bpm] 69 ± 0.27 82 ± 0.47 < 0.001* 69 ± 0.53 69 ± 0.52 0.97 
Systolic BP [mm Hg] 126 ± 0.64 126± 0.44 0.93 123 ± 0.84 130± 0.92 0.2 
Diastolic BP [mm Hg] 76 ± 0.25 78 ± 0.34 0.33 74 ± 0.45 78 ± 0.57 0.24 
Peak VO2 [ml/kg/min]  23 ± 0.12 38 ± 0.24 < 0.0001* 22.2 ± 0.2 23.56 ± 0.27 0.42 
Resting nTTPF (sec) 0.17± 0.002 0.18± 0.003 0.44 0.19± 0.003 0.17± 0.004 0.52 
PCr/γATP ratio 1.28 ± 0.01 2.26 ± 0.02 < 0.0001* 1.27 ± 0.02 1.29 ± 0.01 0.86 
LAV Index [ml/m2] 35.37 ± 0.33 14.68 ± 0.39 < 0.0001* 35.9 ± 0.38 39.45 ± 0.77 0.4 
MWT [cm] 2.31 ± 0.01 - - 2.32 ± 0.02 2.25 ± 0.01 0.58 
F H/O HCM 19 0 - 11 8 0.51 
F H/O SCD 9 0 - 4 5 0.52 
Drug therapy – no.  
 
      
     Beta-blocker 17 0 - 10 7 0.21 
     CC-blocker 24 0 - 11 8 0.53 
     Diuretic 10 0 - 4 5 0.49 
     ACE inhibitor 6 0 - 3 2 0.84 
     ARB 4 0 - 3 1 0.41 
     Warfarin 5 0 - 2 3 0.48 
     Statin 15 0 - 7 7 0.9 
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            Figure 38: Baseline data of myocardial energetic in HCM vs controls. 
 
During submaximal exercise (at a workload that achieved 50% of heart rate reserve),  
nTTPF remained relatively constant in controls (from 0.18 ± 0.003 sec to 0.16 ± 0.002 
sec, [nTTPF = - 0.01 ± 0.004 sec]), but lengthened in patients (from 0.17 ± 0.002 to 
0.34 ± 0.002 sec, [nTTPF = + 0.13 ± 0.003 sec]), p < 0.0001, (Figure 39).  
 
 
         Figure 39: Baseline data of Diastolic ventricular filling in HCM vs controls. 
 163 
Patients exhibited marked exercise limitation compared to controls (peak oxygen 
consumption 23 ± 0.12 vs 38 ± 0.24 ml/kg/min, p <0.0001) (Figure 40).  This remained 
so after excluding patients taking beta blockers (p < 0.0001). 
 
 
Figure 40: Baseline data of peak oxygen consumption in HCM vs controls. 
 
Randomized, double blind, placebo-controlled parallel-group study 
The perhexiline and placebo groups were well matched (Table 17). One patient (on 
placebo) did not complete the study due to poor compliance. 6 patients were 
subtherapeutic and none above the therapeutic range at the end of the study.  
 
 Side effects were restricted to transient nausea (n = 3) and dizziness (n = 2) in the 
perhexiline group and transient nausea (n = 2) and headache (n =1) in the placebo group 
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during the first week of treatment. There were no deaths or major adverse events during 
the study period.  
 
Myocardial energetics 
The mean Cramer-Rao ratios for PCr and ATP for the entire group were 7.5 % and 10.8 
% respectively, indicating satisfactory SNR. 3 patients were excluded from the initial 
analysis due to poor SNR (Cramer Rao ratios >20 %). The PCr/ATP ratio increased 
with perhexiline (1.27 ± 0.02 to 1.73 ± 0.02) vs placebo (1.29 ± 0.01 to 1.23 ± 0.01), p = 
0.003 (Figure 41). The effect of perhexiline on PCr/ATP ratio remained significant 
with inclusion of the 3 patients with poor SNR (p = 0.02).  
 
 
Figure 41: The effects of placebo and perhexiline on myocardial energetic.  
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Diastolic ventricular filling 
Whereas the placebo group showed prolongation of nTTPF during exercise before and 
after therapy (by 0.15 ± 0.007  and 0.11 ± 0.008 sec respectively), in the perhexiline 
group nTTPF lengthened at baseline (by 0.11 ± 0.008 sec) but shortened on treatment 
(by - 0.01 ± 0.005sec) ; p = 0.03  for difference between the perhexiline and placebo 
response (Figure 43 and Figure 42).   
 
 
Figure 42: The effects of Placebo on diastolic ventricular filling.  
nTTPF changes in healthy controls (dotted lines)  are shown for comparison.   
 
Exercise capacity (peak oxygen consumption) 
Peak VO2 at baseline was similar in the perhexiline and placebo groups (Table 17). After 
treatment, Peak VO2 fell by 1.23 ml/kg/min in the placebo group (from 23.56 ± 0.27 to 
22.32 ± 0.27 ml/kg/min), but increased by 2.09 ml/kg/min in the perhexiline group 
(from 22.2 ± 0.2 to 24.29 ± 0.2 ml/kg/min), p = 0.003 (Fig. 3D).   
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Figure 43: The effects of perhexiline on diastolic ventricular filling.  
nTTPF changes in healthy controls (dotted lines) are shown for comparison. 
 
 
 
Figure 44: The effects of placebo and perhexiline on exercise capacity.  
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Symptomatic Status 
 MLHF questionnaire score showed an improvement in the perhexiline group (from 36.13 
± 0.94 to 28 ± 0.75) but did not change in the placebo group (from 36.86 ± 1.21 to 33.6 ± 
1.25 p=0.69), p < 0.001 for difference in response between placebo and perhexiline. 
NYHA score showed an improvement in the perhexiline group (from 2.67 ± 0.02 to 1.92 
± 0.02 p < 0.001) but did not change in the placebo group (from 2.52 ± 0.2.04 to 2.45 ± 
0.04 p=0.78), p < 0.001. More patients in the perhexiline than in the placebo group had 
improvements in NYHA (67% vs. 30%) and fewer had worsening (8% vs. 20%), 
p<0.001, (Figure 45 and Figure 46). 
 
 
 
Figure 45: The effects of placebo and perhexiline on MLHF questionnaire score. 
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Figure 46: The effects of placebo and perhexiline on NYHA score. 
 
Discussion  
This study confirms that patients with symptomatic non-obstructive HCM manifest a 
cardiac energy defect (reduced PCr/ATP ratio) accompanied by a slowing of the 
energy-dependent early diastolic LV active relaxation during exercise (prolongation of 
nTTPF). Consistent with the hypothesis tested, the metabolic modulator perhexiline 
augmented myocardial energetics, corrected the abnormal prolongation of nTTPF on 
exercise, improved symptoms and increased the functional capacity (peak VO2).  
 
The observation that symptomatic patients with HCM manifest impaired myocardial 
energetics (Figure 38) is an expected consequence of the biophysical properties of HCM 
mutations and accords with previous animal and human studies 
32-36
. Thus although the 
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pathogenesis of HCM has been varyingly attributed to increased sarcomeric Ca2+ 
sensitivity, ATPase activity, and aberrant cross-bridge dynamics 
266, 268
 with 
complications such as oxidative stress 
274
 and altered sarcomeric phosphorylation 
275, 276
, 
a common feature of such studies is the excessive energetic cost of tension generation 
by sarcomeric mutations 
267, 269
. Moreover, the failure to preserve myocardial high-
energy phosphates in asymptomatic 
34
 and pre-hypertrophic HCM 
32
, is consistent with 
the proposal that energy deficiency contributes to the pathogenesis of disease 
270
. The 
resulting energy deficiency may contribute to left ventricular hypertrophy in HCM, as 
seen in other primary disorders of myocardial energy deficiency (e.g. mitochondrial 
disorders and Friedreich‘s ataxia) 277.  
 
Since the heart has a very high energy requirement 
278
, cardiac energy deficiency would 
be expected to translate into physiological defects such as a slowing of energy-
dependent 
279
 early diastolic relaxation. Thus whilst in control subjects, the nTTPF 
remained approximately constant between rest and exercise, in HCM nTTPF 
paradoxically lengthened as heart rate increased (Figure 39). This slower filling in the 
context of the reduced diastolic filling time reduces cardiac output and limits exercise 
capacity 
15
.  
 
Perhexiline inhibits the metabolism of free fatty acids and enhances myocardial 
carbohydrate utilisation by suppressing carnitine palmitoyl transferase (CPT) I and II, 
which are crucial for the uptake of long chain fatty acids into mitochondria 
38, 99, 272
. 
While perhexiline‘s mechanism(s) of action is likely to be complex, its primary action 
in diverting myocardial metabolism towards carbohydrates, especially in the context of 
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myocardial oxygen limitation (e.g. due to microvascular dysfunction), 
271
 is predicted to 
enhance the efficiency of myocardial energy generation 
280, 281
. Exploiting this effect, 
agents which modify substrate
 
utilization (e.g. trimetazidine and perhexiline) and 
enhance myocardial energetics, have clinical efficacy in the energy starved state of heart 
failure 
66, 233, 278
. The coexistence of augmented energetic status with substantial 
improvements in diastolic filling, symptoms and exercise performance (~2 ml/kg/min in 
peak VO2) are consistent with a causal relationship. These improvements are clinically 
important, and are comparable in magnitude to those seen with successful gradient 
reduction in obstructive HCM (~3 ml/kg/min).
282, 283
  
 
In this study perhexiline (or placebo) was added to standard medical therapy. Such 
therapy (e.g. beta-blockers), might have affected the cardiovascular response of 
participants to exercise. To account for this potential confounder all pertinent 
physiological parameters were corrected for heart rate. In addition, the statistical 
significance of the results remained unchanged irrespective of whether patients on beta-
blockers were included or excluded from the analysis. Similarly, patients with flow 
limiting epicardial coronary disease and diabetes were excluded to avoid the 
confounding influence of impaired cardiac energetic status associated with these 
disorders 
236
. Moreover, multiple objective and independent parameters (i.e. PCr/ATP, 
nTTPF and VO2) were assessed, to obviate the biases that may confound interpretation 
of phase 2 trials in uncommon disorders.   
 
The PCr/γATP ratio was measured at rest (current technology does not permit reliable 
dynamic measurements). We speculate however that the impact of metabolic 
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modulation on PCr/γATP ratios would be more striking during exercise. To further 
substantiate the 
31
P MRS findings, analyses were performed both including and 
excluding studies with unacceptable signal-to-noise ratios (Cramer-Rao >20%); the 
results remained statistically similar under both circumstances.  
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CHAPTER 9: GENERAL DISCUSSION  
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The myocardium is a metabolic omnivore, which mainly uses fatty acids and glucose 
for generation of Adenosine-5'-triphosphate (ATP), Figure 47. Myocardial metabolism 
is altered in heart diseases and plays a key role in the pathogenesis and progression of 
these diseases. Recently, there has been a great deal of interest in the role of 
disturbances in cardiac and skeletal energetics in the pathophysiology of heart diseases 
and of therapeutic potential of metabolic modulation. 
 
The aim of this PhD work was to assess the myocardial and peripheral metabolic status 
and to examine their causative role in the pathophysiology of heart diseases especially 
HCM patients. Furthermore, we focused on the potential role of metabolic modulator, 
perhexiline, in the management of these symptomatic HCM patients.  
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Figure 47: Myocardial ATP production.   
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Initially, we used NIRS to provide a non-invasive assessment of peripheral oxygen kinetics 
in CHF patients. [Oxy-Hb] and [HbT] were significantly reduced at rest in CHF patients as 
compared to age matched controls (Table 5). However, there were no significant 
differences in resting oxygen saturation or [Deoxy-Hb] between the two groups (Table 5).  
We showed that there is a significant reduction in resting oxygen consumption per gram of 
tissue in skeletal muscle of patients with CHF. This is unlikely to be due to skeletal muscle 
underperfusion as we measured oxygen consumption under conditions of arterial 
occlusion. More importantly, we expressed oxygen consumption measurements per 100 
grams of forearm tissue to account for reduced skeletal muscle mass in heart failure 
patients as a potential confounder. We speculate that reduced skeletal muscle oxygen 
consumption observed in this study could be due to combination of intrinsic factors such as 
mitochondrial dysfunction, altered skeletal muscle substrate utilisation and skeletal muscle 
composition.  Further histological and biochemical studies of muscle biopsy will be needed 
to examine the underlying mechanisms responsible for these observations.  We conclude 
that NIRS has the potential to be an important clinical tool in assessing the severity of 
skeletal muscle metabolic impairment in heart failure, the progression and also response to 
treatment.    
 
HCM is often associated with reduced exercise
 
capacity.  We used STE to examine the 
importance of left ventricular strain, twist and untwist rates as predictors of exercise 
capacity in HCM patients.  Despite normal LVEF, there was a significant impairment of 
strain in all directions (longitudinal, circumferential and radial) and delayed untwisting 
in 56 HCM patients compared to 43 age and gender matched controls (Table 8 and 
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Table 9). While LV diastolic dysfunction is believed to be the predominant cause of 
exercise limitation in HCM patients 
15
, we found that peak V02 correlates significantly 
with markers of both left ventricular systolic and diastolic function (Figure 24). 
Interestingly, there were no significant correlations between peak V02 and other resting 
echocardiographic parameters such as LV mass index, MWT and LV volume index 
(Figure 23). In summary, STE imaging demonstrated a marked impairment of both 
systolic and diastolic LV function and both were significant determinants of exercise 
capacity.  These data provide new insights for the mechanism of exercise limitation in 
patients with HCM using resting echocardiographic parameters. 
 
 
In order to assess in vivo cardiac energetic status, we used MRS technology for the 
measurement of the PCr/γATP ratio. Conventionally, 31P magnetic resonance 
spectroscopy (MRS) at 1.5 Tesla is used to measure in vivo high energy phosphate 
myocardial kinetics. Recently, we acquired the state of art MRI machine (Philips 
Achieva), which operates at a higher magnetic field (3 Tesla).  This enables us to 
improve the sensitivity and specificity of the cardiac spectra by increasing the SNR and 
spectral resolution. In fact, our present study showed that 
31
P MRS of the myocardium 
at 3T is feasible and allows for reliable determination of high energy phosphate kinetics. 
Our reproducibility data showed that the method is robust and might be used for clinical 
diagnostics as well as for clinical studies. However, to take full advantage of increased 
SNR and spectral separation at 3T as compared to 1.5T advances in shimming, coil and 
RF pulse design are necessary.  
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Using MRS technology, we showed that HCM patients have reduced cardiac energetic 
status (Figure 30). Consistent with previous study, we showed a paradoxical slowing of 
LV relaxation on exercise in HCM patients as comparing to shortening in controls 
15
. 
Furthermore, we demonstrated a failure in VVC response on exercise in these HCM 
patients (Figure 32). Impaired cardiac energetics inversely correlated with VVC 
response and with abnormal prolongation of LV relaxation whereas it correlated 
positively with exercise capacity (peak V02) (Figure 35). We conclude that reduced 
cardiac energetics contribute significantly to the abnormal active relaxation and 
impaired VVC response on exercise resulting in reduced exercise capacity.  Based on 
these findings, we proposed that augmenting cardiac metabolism may have a potential 
role in the management of symptomatic non-obstructive HCM patients who are 
refractory to current treatment and not suitable for any other therapeutic options.  
 
The pharmacologic treatment of HCM patients has remained the same for over 30 years 
since beta blockers and calcium blockers were introduced to treat this condition. The 
only other significant addition has been the implantable cardioverter defibrillator (ICD) 
for patients at high risk of sudden death. Treatment options in symptomatic patients 
with the non obstructive form of the disease are more limited. Most treatments in this 
group aim to improve diastolic filling by lowering heart rate, but this can reduce the 
cardiac output response to exercise in some patients and as a result increase exertional 
limitation. Furthermore, these therapies do not prevent the progressive deterioration in 
left ventricular diastolic and systolic function that occurs in significant minority of 
patients. Hence, there is a strong need for a novel pharmacological approach especially 
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for symptomatic non-obstructive patients who are not suitable for any surgical or 
percutaneous intervention.  
 
We designed a placebo controlled, double blind, randomized study to evaluate the 
impact of the metabolic modulator, perhexiline 
280, 284
, on cardiac energy status in HCM, 
and to assess whether any ensuing energetic changes were accompanied by correction of 
the diastolic abnormalities and improvement in exercise capacity in symptomatic non-
obstructive HCM patients. Our results support the hypothesis that HCM is, at least in 
part, a disease of energy deficiency (Figure 48).   
 
We showed that patients with symptomatic HCM manifest a cardiac energy defect at 
rest (reduced PCr/γATP ratio). This defect was accompanied by a slowing of the 
energy-requiring early diastolic LV active relaxation during exercise (prolongation of 
nTTPF (Figure 39). The metabolic modulator perhexiline resulted in significant 
myocardial energy augmentation (Figure 41). Supporting a causative role for energy 
deficiency in the pathophysiology of HCM, this energy augmentation was accompanied 
by striking normalisation of HCM‘s characteristic ―paradoxical‖ nTTPF-prolongation in 
exercise (Figure 43). Further supporting the hypothesis that energy deficiency 
contributes to the sequelae of HCM, perhexiline significantly improved the symptoms 
(by ~ 0.8 NYHA units), and myocardial oxygen consumption (by ~ 2 ml/kg/min) in 
symptomatic HCM patients on standard therapy (Figure 46 and Figure 44, respectively). 
These improvements are substantial and are similar to the benefits seen with septal 
myectomy and ablation in obstructive HCM in some studies (~3 ml/kg/min).
282, 285
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Figure 48: The causative role for energy deficiency in the pathophysiology of 
HCM.  
 
In contrast, although pharmacological therapies such as beta-blockers and calcium 
channel antagonists are extensively used 
264, 265
, evidence for their use, is largely derived 
from small, uncontrolled, observational studies with diverse (hemodynamic) endpoints 
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in heterogeneous patients (often with obstruction). Our study, which is comparable to 
the most rigorous of existing trials 
286
, is the only double-blind randomised controlled 
(RCT) study with robust biochemical, physiological and clinical endpoints, supporting a 
novel therapeutic strategy in symptomatic HCM. 
 
In summary, metabolic modulation by perhexiline augmented myocardial energetics, 
and normalised diastolic ventricular filling which translated into significant subjective 
(NYHA classification and MLHFQ score) and objective (Peak VO2) clinical 
improvement in patients with symptomatic non obstructive HCM, a condition for which 
there are currently limited therapeutic options. Importantly, this encouraging efficacy 
was achieved with few side effects, perhexiline plasma monitoring and dose titration 
prevents the longer term hepatotoxicity and neuropathy that may occur in slow drug 
metabolisers 
280
.   
 
Limitation of studies 
The relevance of changes in twist and untwist during exercise would be interesting to 
examine,
 
however we have demonstrated that even resting measurements of strain and 
untwist were significant predictors of exercise capacity. We have been unable to 
reliably measure these parameters during exercise due to several technical difficulties. 
First of all, it was hard to maintain the same heart rate during exercise while acquiring 
apical and basal short axis echocardiographic images which are crucial for the 
measurement of twist and untwist. Furthermore, exercise exaggerates the
 
issue of 
through-plane motion, particularly at the basal short axis level which is again vital for 
twist measurement.  In addition, the current STE analysis software has insufficient 
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temporal
 
resolution for higher heart rate during exercise. It optimally operates at frame 
rate of 40-100 frames per second which is adequate only for resting studies.  Moreover, 
excessive respiratory movement
 
may degrade the quality of images as compared to the 
resting images.  Further advances in the STE technique (e.g. 3D Speckle Tracking with 
higher temporal resolution) are required to resolve these issues.   
 
In the STE study, we report that there are no significant differences in twist between 
non-obstructive HCM patients and controls (Table 9). The absence of significant 
differences in LV twist observed in this study could be explained by the increased 
through-plane motion at the base of the heart. However, we showed a significant 
reduction in apical rotation rates during both systole and diastole. Previous study 
showed that apical rotation represents the major contributions to LV twist 
287
.  
 
Although the heart rate is slower in the HCM group (Table 6), all longitudinal, radial 
and circumferential strain parameters were independent of heart rate because we 
measured peak values rather than timing. Untwist timing parameters were corrected for 
heart rate by converting R-R interval to 100 % as previously described 
288
.  
 
Thus although the consistent improvement cardiac status using multiple reliable 
independent parameters (i.e. PCr/ATP, nTTPF, NYHA, MLHFQ and VO2) in our 
randomised clinical trial provides reassurance against the possibility of a false positive 
result, a notable feature of this study is the contrast between the robust biochemical, 
physiological and symptomatic improvements and the clinically significant but less 
prominent improvement in VO2. The causes for this dissociation are likely to be multi-
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factorial but probably relate, in part, to the relatively short period of perhexiline (~4.6 
months) used herein to elucidate the mechanisms underlying HCM. Thus despite the 
improvements observed in cardiac physiology with perhexiline, there may have been 
inadequate time for extra-cardiac improvement (i.e. detraining of skeletal muscle 
persisted).
282
 In this context, HCM hearts may no longer have been the limitation to 
exercise (VO2).  
 
 
To mitigate some of the challenges encountered by studies of this size in disorders of 
relatively low prevalence and to be maximally informative, the present study focussed 
on as homogenous a group of patients as possible. For example, one source of 
heterogeneity derived from the fact that perhexiline (or placebo) was added to standard 
medical therapy. Such therapy (e.g. beta-blockers), might have affected the 
cardiovascular response of participants to exercise. To account for this potential 
confounder, firstly, all pertinent physiological parameters were corrected for heart rate. 
In addition, the statistical significance of our results remained unchanged irrespective of 
whether patients on beta-blockers were included or excluded from the analysis. 
Similarly, patients with flow limiting epicardial coronary disease and diabetes were 
excluded to avoid the confounding influence of impaired cardiac energetic status 
associated with these disorders 
289
. Moreover, multiple objective and independent 
parameters (i.e PCr/ATP, nTTPF and VO2) were assessed, as previously advocated, to 
obviate the biases that have confounded existing therapeutic HCM studies 
282, 286
. 
However, in contrast to the nTTPF and VO2, the PCr/γATP ratio, representing a 
surrogate of cardiac energetic status, was measured at rest (current technology does not 
permit reliable dynamic measurements). We speculate that the impact of metabolic 
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modulation on PCr/γATP ratios would be more striking during exercise. To further 
substantiate the 
31
P MRS findings, analyses were performed both including and 
excluding studies with unacceptable signal-to-noise ratios (Cramer-Rao >20%); the 
results remained statistically similar under both circumstances. Finally, while it is 
formally possible that the pathway(s) through which perhexiline augmented energetics 
were distinct from those which led to an improvement in physiology, by virtue of 
perhexiline‘s predominant mode of action being to modify metabolism, perhexiline‘s 
benefits are likely to be, as assumed, through energy augmentation.  
 
 
Future research 
One interesting area of future research is to examine the mechanisms involved in the 
beneficial response of perhexiline on cardiac energetics. It would be important to 
demonstrate a reduction in myocardial fat oxidation concurrent with an increase in 
glucose utilization. It be would be necessary to have a measure of myocardial substrate 
utilization such PET scan to non-invasively evaluate myocardial glucose and FA 
utilization and myocardial VO2. Alternatively, this could be achieved invasively using 
cardiac catheterisation to assess the cardiac respiratory quotient. Such studies would 
directly demonstrate if the mechanisms for the beneficial impact of perhexiline were the 
result of a shift in substrate metabolism and an increase in cardiac efficiency. 
Furthermore, perhexiline could have a multitude of effects in addition to inhibiting fatty 
acid oxidation. It would be helpful to know what happens to circulating levels of 
glucose, triglyceride, insulin and free fatty acids before and after perhexiline treatment. 
The limited duration of the drug treatment in this study does not allow ascertaining if, as 
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is the case of secondary LVH where treatment with drugs such as ACE inhibitors results 
in regression of tissue hypertrophy, treatment with perhexiline induces any regression in 
LVH in patients with HCM.  Although double-blind randomised controlled clinical trial 
of this size are uncommon in HCM pharmacological studies,
286, 290
 and despite the 
consistently positive hence promising results across diverse cardiac parameters in 
symptomatic HCM, the clinical implementation of metabolic therapy in HCM must 
await further confirmation. Larger formal trials in a broader range of patients will be 
necessary to establish the long-term efficacy and safety of rapidly implementable 
metabolic modulators (e.g. with perhexiline, trimetazidine or other metabolic 
modulators 
38
). Furthermore, successful metabolic modulation in HCM may act as an 
exemplar for assessing the physiological and clinical benefits of energy augmentation 
through metabolic modulation in more common myocardial disorders, also recognised 
to be associated with energy deficiency (e.g. HF with normal ejection fraction).  
 
To address some of these important issues, we wrote a research proposal which was 
successfully awarded a British Heart Foundation project grant. In this proposal we will 
assess the cardiac function, remodelling/reverse remodelling (by cardiac Magnetic 
Resonance Imaging MRI) and cardiac energetic status (by cardiac Magnetic Resonance 
spectroscopy MRS), cardiac efficiency (via pressure-volume loops) and substrate 
utilization (left and right heart catheterization) pre and post six months of perhexiline 
therapy in patients on optimal conventional medications for heart failure (Prof M 
Frenneaux, Prof A Wagenmakers and Dr K Abozguia. British Heart Foundation project 
grant [PG/06/105/21468] entitled ‗Modification of Myocardial Substrate Utilisation as a 
Therapy for Heart Failure‘ [£235,616], Aug 2006).    
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Information sheet for participants 
Study title: Perhexiline Therapy in Patients with Hypertrophic Cardiomyopathy 
 
Researchers: Prof M Frenneaux, Prof H Watkins, Dr P Elliott, Dr Z Yousef and Dr K 
Abozguia 
 
I am writing to invite you to take part in a study we are conducting.  We intend to 
investigate a drug that may be beneficial to you.  Your treatment will not be affected in 
any way if you decide not to take part in this study. 
 
What is the purpose of this study? 
We have previously shown that a drug called perhexiline improves symptoms of 
breathlessness and also improves the heart‘s performance in certain types of heart 
disease.  We now wish to test whether it is also effective in a heart condition called 
Hypertrophic Cardiomyopathy. 
 
Why have I been chosen? 
You have been chosen because you have Hypertrophic Cardiomyopathy and you are 
limited in your everyday activities by breathlessness or fatigue despite your current 
treatment.  
 
Who is organising the study? 
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This is a multi-centre study organised by University of Birmingham, University of 
Oxford, University Hospital of Wales and University College London Hospitals.  The 
Department of Cardiovascular Medicine at University of Birmingham is leading the 
study.  Prof Michael Frenneaux (Head of Department) is the chief investigator. 
 
What will happen to me if I take part? 
You will be asked to arrive between 9 am to 3 pm at the Department of Cardiovascular 
Medicine, University of Birmingham, which is on the site of Queen Elizabeth Hospital.  
You will receive a clinical examination and a blood sample (total of 15 ml) will be 
taken.  In addition, an echocardiogram (a non-invasive ultrasound scan of the heart) will 
be performed.  You will then be asked to exercise on a treadmill wearing a mask to 
measure the amount of oxygen you consume. You will also be asked to fill in a 
questionnaire, which gives an indication as to the severity of your symptoms.  These 
tests will take a total of one and a half hours. Then you will have a nuclear heart scan.  
This is a test in which your red blood cells will be labelled with a very small amount of 
radioactivity and a special 'Gamma Camera' is used to obtain pictures of your heart at 
rest and during exercise.  The test will last for 1 ½ hours and you may feel slight 
discomfort during venflon (Needle) insertion in your arm, the insertion of the venflon 
and its associated pain will take less than two minutes.  Otherwise it‘s a painless test 
and side effects are extremely rare. The method of administration has been performed 
safely by our team for a number of years now without complications in just under four 
hundred subjects.  The amount of radiation that you will be exposed to is approximately 
the same as the background of radiation you will receive if you lived in Cornwall (UK) 
for one year and is the same as the amount you would receive from a CT scan of your 
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chest.  Then you will have Magnetic Resonance Scans of your heart if appropriate.  
These Magnetic Resonance Scans will be carried either in Birmingham University 
Imaging Centre or John Radcliffe Hospital, Oxford (optional).  Scanners that are used 
for the Magnetic Resonance tests are shaped like a polo mint and some patients find this 
scanner slightly claustrophobic. The first test (Magnetic Resonance Imaging scan of the 
heart) will measure the heart size and function at rest.  For this test, you will lie 
comfortably on your back, and we will ask you to hold your breath for a few seconds 
during the scan. This test will take approximately 40 minutes. In the next test (Magnetic 
Resonance Spectroscopy of the heart) we will look at the metabolism of the heart.  We 
will ask you to lie on your stomach, and you do not need to hold your breath. This study 
will last about 45 minutes.  
 
You will then be given either perhexiline or a placebo (a sugar tablet that does not 
contain any active treatments) to be taken daily for three months.  The allocation to 
perhexiline or placebo is random (50:50).  Neither the doctor conducting the study nor 
you will know whether you are taking perhexiline or placebo.  A code that tells us 
which tablet you are taking will be broken at the end of the study, or sooner should the 
need arise.  While on the tablet you will need to have blood tests taken in order to avoid 
any potential side effects of the treatment.  The blood tests will be taken 7 days after 
you start taking the treatment to measure the concentration of the drug in your blood 
and this will be followed by another blood test after 4 weeks.  If the level of the drug 
reaches a steady state then the blood tests will only be repeated at 3 months.  If the level 
of the drug has yet to reach a steady state we will continue to monitor your blood levels 
every 4 weeks until the level of the drug reaches a steady state. These blood tests can be 
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carried out in your GP surgery (provided they agree to do so), otherwise it will be 
carried out by a member of our research team in one of the three centres taking part in 
this study (the centre which is most convenient for you). The doses of perhexiline will 
be changed according to the results of the blood tests.  Dose adjustments will also be 
made in patients taking placebo tablets in order that neither you nor we know which 
treatment you are taking. At the end of three months you will be seen again at the 
Department of Cardiovascular Medicine, University of Birmingham, for a final set of 
blood tests, echocardiography, nuclear scan and exercise test.  Another set of MR scans 
will be carried out in the same centre you had your initial set.  After the last scan the 
medication will be discontinued. 
 
What do I have to do? 
Study Day 1: Baseline investigations. These are blood tests, heart 
tracing, Ultrasound heart scan, exercise test, nuclear heart 
scan , completing a questionnaire and Magnetic 
Resonance scans (MRI and MRS) of the heart.  
 
We will be happy to organise these studies over 2 days if you wish to do so.  You will 
then be randomised to receive either the active drug (perhexiline) or a placebo.  You 
will be required to take this drug daily for three months.  While you are taking the drug, 
you will need monitoring of the blood level of the drug.  This will be done through 
blood tests, which you will have by attending the hospital or by seeing your General 
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Practitioner.  This is explained in detail above.  Having been on treatment for 3 months, 
you will then be asked to attend for the following studies: 
 
Study Day2 : Repeating of Baseline investigations. These are blood 
tests, heart tracing, Ultrasound heart scan, exercise test, 
nuclear heart scan,   completing a questionnaire and 
Magnetic Resonance scans (MRI and MRS) of the heart.  
 
We will be happy to organise these studies over 2 days if you wish to do so.   
 
End of Study: Following completion of all studies, the drug will be 
discontinued, and the study will end. 
 
We will pay your travel and accommodation expenses.  If you require a carer for 
medical reasons to accompanying you during this study, we will also reimburse the 
carer travel and accommodation expenses. 
 
What is perhexiline? 
In the 1970s, perhexiline was shown to be an effective drug at relieving symptoms of 
angina and breathlessness in some forms of heart disease.  There were cases of liver or 
peripheral nerve damage which eventually resulted in the withdrawal of perhexiline in 
many countries around the world.  In approximately 1980, it was found that the 
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probability of developing toxic reactions to perhexiline was closely related to plasma 
drug levels.  A simple assay for drug levels is available.  It has been shown that with 
regular monitoring of perhexiline levels, the risk of either liver damage or of peripheral 
nerve damage can be reduced to virtually zero.  In our experience with perhexiline in 
Cardiff and the experience of its widespread use in Australia, no serious adverse effects 
have been observed.  Recently, there have been studies performed suggest that it works 
by making the heart muscle more efficient and so reducing the amount of oxygen 
required. It is through that mechanism that we suspect it could also be useful at reducing 
breathlessness caused by Hypertrophic Cardiomyopathy. 
 
 
 
What are the potential side effects of perhexiline? 
Minor nausea and dizziness can occur in the first few days but usually pass. Long-term 
side effects (liver damage and nerve damage) are extremely rare and are avoided by 
monitoring blood levels and adjusting the dose if necessary.  Perhexiline has been 
shown to be a safe drug provided blood levels are monitored on a regular basis and drug 
dosage is adjusted accordingly.  A doctor will inform you on the correct dose 
adjustment based on your blood levels. You will be asked to report any symptoms of 
muscle weakness, limb numbness or jaundice to the doctor.  A 24-hour phone number 
will be provided in case of emergencies. 
 
What are the possible benefits of taking part? 
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You may find perhexiline useful at relieving your symptoms. However, there is a 50% 
chance that you will be on Placebo which may not affect your symptoms.  Your 
participation in this study will help to broaden our understanding of Hypertrophic 
Cardiomyopathy, which is a condition affecting many people in the United Kingdom.  
We also hope that the study will demonstrate to us how this treatment works, so that we 
may develop similar treatments in the future which do not require regular blood tests to 
avoid side effects.  
 
Who will have access to the data and study results? 
Prof M Frenneaux will be ultimately responsible for the data and study results.  The 
research staff at the Departments of Cardiovascular Medicine, within the three study 
sites will have control of the data.  Ethics Committees, national and international 
regulatory authorities, which will review information on the drug and study, may also 
inspect the results.  The data will be kept in a locked filing cabinet in the Department of 
Cardiovascular Medicine, University of Birmingham.  In addition, information about 
you will be kept confidential, and your medical records will not be made public.  We 
aim to publish the research in peer reviewed journals and the abstracts are usually 
available on the internet to the public.  If the results from this trial should be published, 
your identity will be kept completely confidential.  If at the end of the study you would 
like a copy of the published paper, this can be sent to you on request.  
 
Are there compensation arrangements if something goes wrong? 
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In the unlikely event of your health deteriorating in any way as a result of negligence, 
you may submit a claim to the University Hospital Birmingham NHS Trust for 
compensation to be considered.  If you are harmed due to someone‘s negligence, then 
you may have grounds for a legal action.  There is no cover for non-negligent harm but 
regardless of this, if you wish to complain, or have any concerns about any aspect of the 
way you have been approached or treated during the course of this study, the normal 
NHS complaints mechanisms are available to you.  If you are covered by Private 
Medical Insurance you should contact them to determine whether your cover would be 
affected in any way by taking part in this research. 
 
What happens if I do not want to participate or I change my mind during the research 
study? 
You do not have to participate in this study.  If you decide not to participate or change 
your mind later on; you can withdraw at any time.  Your withdrawal will not affect your 
subsequent treatment in any way. 
 
What if new information becomes available? 
You would be informed by telephone of any new developments. 
 
What happens at the end of the study?   
At the end of the study the tablet you were taking for three months will be discontinued.  
We can‘t guarantee that this medication will be available to you at the end of the study.  
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If this study produces positive results, we will negotiate with the Hospital Trust to try to 
continue the drug. 
 
Will my GP be informed?  
Yes. Your GP will receive a letter explaining the objectives of the study. 
 
If you have any complains during the study please do not hesitate to let me know.  
 
If you are unhappy about our approach, manners, or the way we have dealt with any of 
your requests, please feel free to contact the chief investigator Professor M Frenneaux in 
the Department of Cardiovascular medicine, University of Birmingham (Tel.0121–
4146926). 
 
If you are interested in taking part or if you have more questions or do not understand 
something please contact: 
 
 
Dr Khalid Abozguia                                      
Department of Cardiovascular Medicine      
University of Birmingham                            
Edgbaston, Birmingham                                
B15 2TT                                                        
Tel: 01214145916                                         
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In cases of emergencies Dr K Abozguia can also be contacted on his mobile phone 
  
 
Finally, thank you very much for taking the time to consider taking part in this study 
and we will be grateful if you could send the response form in the self-addressed paid 
for envelope. 
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Consent form 
Patient Identification/Study Number: ____________________  
Project Title: Perhexiline therapy in patients with Hypertrophic Cardiomyopathy. 
Researchers: Prof M Frenneaux, Prof H Watkins, Dr P Elliott, Dr Z Yousef and Dr K Abozguia 
Please initial box 
1. I confirm that I have read and understand the information sheet dated 01-05-2007  
Version 4 for the above study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
 time, without giving any reason, without my medical care or legal rights being affected. 
3. I understand that sections of my medical notes relating to participation in the study  
 may be inspected by responsible individuals from the three study centres  mentioned  
        above or from regulatory authorities.  All personal details will be treated as  
 STRICTLY CONFIDENTIAL. I give permission for these individuals to have 
 access to my records. 
 
4. I am willing that my general practitioner is notified of my participation in this research. 
 
5. I agree to take part in the above study and am satisfied that I have been given  
 sufficient time and information to reach this decision. 
___________________       ______________     ______________________________ 
Name of Research Subject                     Date                       Signature  
 (Please print) 
____________________       ______________      ______________________________ 
Name of Witness to Signature                    Date                      Signature  
(Must not be member of research team) 
(Please print) 
____________________    _____________      ______________________________ 
Name of Research Team member              Date                                    Signature  
(Please print) 
 
 
 
 
 
 
Perhexiline therapy in patients with                       version 4                                            01-05-2007   
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Response Form 
Thank you for reading the enclosed information sheet.  Once you have reached a 
decision I would be grateful if could complete and return this form, indicating whether 
you would like 1) To participate, 2) To have further information or 3) To not 
participate, by ticking the appropriate box below.  Complete as many details as you can. 
Please return the completed form in the enclosed stamped addressed envelope. 
 
    Name: __________________________________________________________ 
    DOB:          __________________________________________________________ 
    Address: _________________________________________________________ 
  __________________________________________________________ 
  ________________________________________________________ 
Tel:    _________________Business Tel: ______________________________       
Mobile:      ________________   Email address:_____________________________ 
GP Name: _____________________________________________ 
    GP Address: _________________________________________________________ 
                           ________________________________________________________ 
    Tel: ____________________________ Fax:  ________________________________ 
     
    I agree to participate in the study             (Please tick one box) 
 
    I would like further information  
    
    I do not wish to participate in the study    
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